US20150328479A1 - System and method for the photodynamic treatment of burns, wounds, and related skin disorders - Google Patents
System and method for the photodynamic treatment of burns, wounds, and related skin disorders Download PDFInfo
- Publication number
- US20150328479A1 US20150328479A1 US14/807,653 US201514807653A US2015328479A1 US 20150328479 A1 US20150328479 A1 US 20150328479A1 US 201514807653 A US201514807653 A US 201514807653A US 2015328479 A1 US2015328479 A1 US 2015328479A1
- Authority
- US
- United States
- Prior art keywords
- skin
- collagen
- mmp
- cells
- light
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 39
- 208000027418 Wounds and injury Diseases 0.000 title description 31
- 206010052428 Wound Diseases 0.000 title description 15
- 208000017520 skin disease Diseases 0.000 title description 3
- 238000002428 photodynamic therapy Methods 0.000 title 1
- 230000005670 electromagnetic radiation Effects 0.000 claims abstract description 33
- 230000005855 radiation Effects 0.000 claims abstract description 27
- 230000003287 optical effect Effects 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 description 91
- 210000004027 cell Anatomy 0.000 description 46
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 39
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 39
- 206010051246 Photodermatosis Diseases 0.000 description 37
- 230000008845 photoaging Effects 0.000 description 37
- 230000014509 gene expression Effects 0.000 description 36
- 230000000694 effects Effects 0.000 description 34
- 210000002950 fibroblast Anatomy 0.000 description 34
- 102000008186 Collagen Human genes 0.000 description 27
- 108010035532 Collagen Proteins 0.000 description 27
- 230000032683 aging Effects 0.000 description 27
- 229920001436 collagen Polymers 0.000 description 27
- 230000006378 damage Effects 0.000 description 25
- 238000003757 reverse transcription PCR Methods 0.000 description 24
- 102000012422 Collagen Type I Human genes 0.000 description 23
- 108010022452 Collagen Type I Proteins 0.000 description 23
- 238000011282 treatment Methods 0.000 description 23
- 230000001965 increasing effect Effects 0.000 description 19
- 208000014674 injury Diseases 0.000 description 19
- 230000037361 pathway Effects 0.000 description 17
- 206010042496 Sunburn Diseases 0.000 description 16
- 238000004519 manufacturing process Methods 0.000 description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 238000002560 therapeutic procedure Methods 0.000 description 14
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 13
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 11
- 230000003712 anti-aging effect Effects 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 11
- 210000004207 dermis Anatomy 0.000 description 11
- 230000029663 wound healing Effects 0.000 description 11
- 201000010099 disease Diseases 0.000 description 10
- 230000007246 mechanism Effects 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 101710172711 Structural protein Proteins 0.000 description 9
- 230000001684 chronic effect Effects 0.000 description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- 206010015150 Erythema Diseases 0.000 description 8
- 239000003963 antioxidant agent Substances 0.000 description 8
- 235000006708 antioxidants Nutrition 0.000 description 8
- 230000005754 cellular signaling Effects 0.000 description 8
- 230000007613 environmental effect Effects 0.000 description 8
- 230000004054 inflammatory process Effects 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 230000000699 topical effect Effects 0.000 description 8
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 210000002615 epidermis Anatomy 0.000 description 7
- 239000003642 reactive oxygen metabolite Substances 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 108010014258 Elastin Proteins 0.000 description 6
- 102000016942 Elastin Human genes 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 229920002549 elastin Polymers 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 230000008439 repair process Effects 0.000 description 6
- 230000037390 scarring Effects 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 5
- 230000003078 antioxidant effect Effects 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 239000000835 fiber Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000025053 regulation of cell proliferation Effects 0.000 description 5
- 230000014493 regulation of gene expression Effects 0.000 description 5
- 229930002330 retinoic acid Natural products 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 235000019154 vitamin C Nutrition 0.000 description 5
- 239000011718 vitamin C Substances 0.000 description 5
- 230000037314 wound repair Effects 0.000 description 5
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 4
- 208000034656 Contusions Diseases 0.000 description 4
- 108010052832 Cytochromes Proteins 0.000 description 4
- 102000018832 Cytochromes Human genes 0.000 description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 4
- 230000037338 UVA radiation Effects 0.000 description 4
- 229930003268 Vitamin C Natural products 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 230000001338 necrotic effect Effects 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 230000036542 oxidative stress Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 231100000241 scar Toxicity 0.000 description 4
- 230000003595 spectral effect Effects 0.000 description 4
- 229960001727 tretinoin Drugs 0.000 description 4
- 230000003827 upregulation Effects 0.000 description 4
- 208000032544 Cicatrix Diseases 0.000 description 3
- 102000000634 Cytochrome c oxidase subunit IV Human genes 0.000 description 3
- 108090000365 Cytochrome-c oxidases Proteins 0.000 description 3
- 241000208125 Nicotiana Species 0.000 description 3
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 3
- 108010050808 Procollagen Proteins 0.000 description 3
- 102100027584 Protein c-Fos Human genes 0.000 description 3
- 239000010426 asphalt Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000008033 biological extinction Effects 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000037319 collagen production Effects 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 231100000321 erythema Toxicity 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000010534 mechanism of action Effects 0.000 description 3
- QUAMTGJKVDWJEQ-UHFFFAOYSA-N octabenzone Chemical compound OC1=CC(OCCCCCCCC)=CC=C1C(=O)C1=CC=CC=C1 QUAMTGJKVDWJEQ-UHFFFAOYSA-N 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 238000007634 remodeling Methods 0.000 description 3
- 229960003471 retinol Drugs 0.000 description 3
- 235000020944 retinol Nutrition 0.000 description 3
- 239000011607 retinol Substances 0.000 description 3
- 230000037387 scars Effects 0.000 description 3
- 230000009759 skin aging Effects 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 230000008833 sun damage Effects 0.000 description 3
- 230000000475 sunscreen effect Effects 0.000 description 3
- 230000008733 trauma Effects 0.000 description 3
- 230000000472 traumatic effect Effects 0.000 description 3
- 230000037303 wrinkles Effects 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- ZKRFOXLVOKTUTA-KQYNXXCUSA-N 9-(5-phosphoribofuranosyl)-6-mercaptopurine Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=S)=C2N=C1 ZKRFOXLVOKTUTA-KQYNXXCUSA-N 0.000 description 2
- 208000009043 Chemical Burns Diseases 0.000 description 2
- 102100025287 Cytochrome b Human genes 0.000 description 2
- 108010075028 Cytochromes b Proteins 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 2
- 101001013150 Homo sapiens Interstitial collagenase Proteins 0.000 description 2
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 description 2
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 2
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 2
- 229940124761 MMP inhibitor Drugs 0.000 description 2
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- 108010031374 Tissue Inhibitor of Metalloproteinase-1 Proteins 0.000 description 2
- 102000005353 Tissue Inhibitor of Metalloproteinase-1 Human genes 0.000 description 2
- 108010018242 Transcription Factor AP-1 Proteins 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000006851 antioxidant defense Effects 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000007248 cellular mechanism Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000002316 cosmetic surgery Methods 0.000 description 2
- 230000000593 degrading effect Effects 0.000 description 2
- 230000001066 destructive effect Effects 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- 230000003467 diminishing effect Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 230000006353 environmental stress Effects 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 210000003780 hair follicle Anatomy 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 235000012661 lycopene Nutrition 0.000 description 2
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 2
- 229960004999 lycopene Drugs 0.000 description 2
- 239000001751 lycopene Substances 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 231100000289 photo-effect Toxicity 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 230000019612 pigmentation Effects 0.000 description 2
- 230000035409 positive regulation of cell proliferation Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000003716 rejuvenation Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000007665 sagging Methods 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000516 sunscreening agent Substances 0.000 description 2
- -1 therapies Substances 0.000 description 2
- 239000003860 topical agent Substances 0.000 description 2
- 229940100616 topical oil Drugs 0.000 description 2
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 101150084750 1 gene Proteins 0.000 description 1
- 230000002407 ATP formation Effects 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- 208000035484 Cellulite Diseases 0.000 description 1
- 208000018380 Chemical injury Diseases 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 208000029767 Congenital, Hereditary, and Neonatal Diseases and Abnormalities Diseases 0.000 description 1
- 102000016736 Cyclin Human genes 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- 102000006312 Cyclin D2 Human genes 0.000 description 1
- 108010058544 Cyclin D2 Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 230000009946 DNA mutation Effects 0.000 description 1
- 102100035784 Decorin Human genes 0.000 description 1
- 108090000738 Decorin Proteins 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 206010069808 Electrical burn Diseases 0.000 description 1
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 description 1
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010026132 Gelatinases Proteins 0.000 description 1
- 102000013382 Gelatinases Human genes 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 101150014058 MMP1 gene Proteins 0.000 description 1
- 108010016165 Matrix Metalloproteinase 2 Proteins 0.000 description 1
- 102000000424 Matrix Metalloproteinase 2 Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101001013152 Mycobacterium avium Major membrane protein 1 Proteins 0.000 description 1
- 101001013151 Mycobacterium leprae (strain TN) Major membrane protein I Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102100030411 Neutrophil collagenase Human genes 0.000 description 1
- 101710118230 Neutrophil collagenase Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 206010049752 Peau d'orange Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 description 1
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 1
- 206010063562 Radiation skin injury Diseases 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- 108700012920 TNF Proteins 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 208000024799 Thyroid disease Diseases 0.000 description 1
- 102000005354 Tissue Inhibitor of Metalloproteinase-2 Human genes 0.000 description 1
- 108010031372 Tissue Inhibitor of Metalloproteinase-2 Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010054880 Vascular insufficiency Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000009692 acute damage Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000003718 aged appearance Effects 0.000 description 1
- 150000004347 all-trans-retinol derivatives Chemical class 0.000 description 1
- 208000002029 allergic contact dermatitis Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000036621 balding Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229940105657 catalase Drugs 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000036232 cellulite Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000009693 chronic damage Effects 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 230000011382 collagen catabolic process Effects 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 108700004333 collagenase 1 Proteins 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 201000010251 cutis laxa Diseases 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000000940 electromagnetic therapy Methods 0.000 description 1
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000005357 flat glass Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- 230000002070 germicidal effect Effects 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- JGPMMRGNQUBGND-UHFFFAOYSA-N idebenone Chemical compound COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O JGPMMRGNQUBGND-UHFFFAOYSA-N 0.000 description 1
- 229960004135 idebenone Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 101150077280 mt-atp6 gene Proteins 0.000 description 1
- 230000003533 narcotic effect Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 108010088694 phosphoserine aminotransferase Proteins 0.000 description 1
- 102000030592 phosphoserine aminotransferase Human genes 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 238000001126 phototherapy Methods 0.000 description 1
- 208000024335 physical disease Diseases 0.000 description 1
- 210000004694 pigment cell Anatomy 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 230000005195 poor health Effects 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 231100000814 pulsed exposure Toxicity 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 230000008263 repair mechanism Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000008399 response to wounding Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 150000004492 retinoid derivatives Chemical class 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000005437 stratosphere Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 108091007196 stromelysin Proteins 0.000 description 1
- 230000036561 sun exposure Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000036575 thermal burns Effects 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 208000021510 thyroid gland disease Diseases 0.000 description 1
- 230000005944 tissue migration Effects 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 229940035936 ubiquinone Drugs 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 208000023577 vascular insufficiency disease Diseases 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/0616—Skin treatment other than tanning
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/065—Light sources therefor
- A61N2005/0651—Diodes
- A61N2005/0652—Arrays of diodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
- A61N2005/0659—Radiation therapy using light characterised by the wavelength of light used infrared
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
- A61N2005/0662—Visible light
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
- A61N2005/0662—Visible light
- A61N2005/0663—Coloured light
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0664—Details
- A61N2005/0667—Filters
Definitions
- This invention relates to method and devices for the photodynamic regulation of cell proliferation and gene expression.
- the invention relates to the reducing, reversing, and/or diminishing the effects of sunburn, thermal burns, chemical burns, radiation burns, various types of wounds, such as traumatic, surgical, laser, chemical peel, cosmetic surgery, warfare agents or injuries, freezing, hypoxia, vascular insufficiency, bruising, chronic ulcers, etc., allergic reactions or contact dermatitis, and various inflammatory diseases.
- Chronological aging i.e., the aging of skin caused by exposure to natural and synthetic light sources, disease, and trauma all bring about changes in the appearance of human and mammalian skin as well as changes in the structure and function of the skin. All living cells, tissues and organs also undergo changes associated with chronological aging, bruising, photo-aging, disease, and trauma. Since the human skin is an organ that is highly visible, the changes associated with these conditions are readily apparent and visible. These changes are reflections of the underlying structural and functional changes.
- UVA ultraviolet A
- UVB ultraviolet B
- UVA ultraviolet
- UUB 290-320 nm
- UVC ⁇ 290 nm
- UVA and UVB sunlight do reach the earth and are believed to be the principal agents of photoaging.
- UVA radiation is further subdivided into UVA 1 and UVA 2. While UVB has been believed to be the primary agent for photoaging, it is now appreciated that certain wavelength ranges within the UVA rays also contribute to changes associated with photoaging.
- Acute environmental injuries include sunburn from UV light and other thermal, chemical, and other types of burns or burn-like injuries. These type of injuries produce not only damaged cells, but dying cells. Damaged cells may either repair the damage and return to normal, repair the damage imperfectly and produce an abnormal or sub-optimally functioning cell, or the cells may die. In the case of sunburn chronic sun-damage accumulates damaged and imperfectly repaired cells to produce what might be termed ‘solar scars’ but we more commonly think of these as ‘wrinkles’. That is a wrinkle is really the result of accumulation of imperfectly repaired cell damage. Likewise the brown ‘liver’ or ‘age spots’ that are common as one ages and photoages are similarly damage to the pigment cells or melanocytes.
- Acute UV injury or sunburn produces dying cells in the upper skin layer or epidermis called ‘sunburn cells’.
- Counting sunburn cells is a classic scientific method to quantify the severity of damage to these keratinocyte cells.
- Therapies which reduce the number of sunburn cells are considered beneficial to diminishing the severity of the injury or repairing or reversing the injury. More generally speaking damaged cells which might recover or die are termed ‘apoptotic’ cells and those cells which are irreversibly damaged and will die are termed ‘necrotic’ cells.
- Treatments which can turn necrotic cells into living cells would be considered treatments which ‘rescue’ or ‘revive’ the cells which are destined for death.
- Such treatments and therapies would have great importance in treating not only acute sunburn, but sub-acute sun damage that leads to accumulated chronic damage.
- the ability to ‘rescue’ dying cells in wounds, burns, etc would have a powerful impact on healing time, scarring or lack thereof, infection risk, and even survival of entire organs or organisms.
- the pertinent arts have, heretofore, been unable to produce a system or method for reviving or rescuing necrotic cells or those in advanced stages of necrosis.
- UVA and UVB light exposure to human skin triggers a series of molecular events including the induction of reactive oxygen species (ROS) in the skin.
- ROS reactive oxygen species
- the skin's reaction to UVA or UVB (or combined) wounding is to repair the wound through the skins wound healing mechanism.
- these wound repair mechanisms are imperfect which is considered by many to be a solar scar.
- chronic solar scarring develops which manifests itself in the visible phenotypic changes termed photoaging, which might also be considered the visible outward evidence of solar scars.
- Photoaging of the skin may occur through acute injury at higher levels, such as what one associates with sunburn. This triggers an inflammatory process in the skin and the associated cellular mechanisms. There is also a more chronic low-level type of injury that does not produce a sunburn reaction, but which produces the changes of chronic photoaging. Other processes, which are known to decrease collagen production and increase collagen-dissolving enzymes, such as tobacco smoking, also are associated with changes that visibly appear, similar to the photoaging from UVA/UVB light. This can be seen strikingly in photographs of identical twins wherein only one twin smoked tobacco for many years.
- UVB radiation in sufficient doses produces reddening or sun burning of the skin.
- the threshold level is typically described as minimal erythema′ dose (MED), typically produced by 290-300 nm UVB wavelengths. As the wavelengths increase they become much less likely to produce the redness and burning reactions and indeed wavelengths of 320 nm are about 100 times as powerful as wavelengths of 340 nm approximately 100 times less powerful than the 290-300 nm range of producing erythema and sunburns.
- the total UVB exposure is more related to the appearance of photoaging and sunburns are more likely to trigger malignant changes in the skin such as malignant melanoma.
- UVA radiation can produce redness, but also produced tanning and these are the wavelengths typically used for the so-called tanning beds.
- UVA radiation is a longer wavelength and is proportionately greater in the early morning and late afternoon and the UUB rays, which are typically most predominant and intense at the midday summer sun time exposure period, UVA radiation may also penetrate certain sun blocks mid certain sunscreens and also window glass on automobiles, thus accounting for the frequently observed greater wrinkling, brown pigmentation and redness and overall aged appearance on the left side of the face than the right in patients who occupationally or recreationally spend considerable time driving a left hand drive motor vehicle.
- the chronological changes and photoaging changes typically are manifest by fine lines and wrinkling of the skin.
- the skin is composed of several layers, the outermost layer is called the stratamocornium (SC), next layer is the epidermis (EPI), and underneath the epidermis lies the dermis (DER).
- SC stratamocornium
- EPI epidermis
- DER underneath the epidermis lies the dermis
- the outer SC serves primarily a barrier function to protect the skin from environmental exposure and also to help minimize water loss from the skin.
- the epidermis serves many important and diverse roles as does the dermis.
- the dermis contains the principal structural proteins of the skin. These proteins are collagen, elastin and ground substance. They are manufactured by the fibroblast cells within the dermis. Fi
- the dermis also contains blood vessels, nerve fibers, oil and sweat glands, hair follicles and many other important components.
- Fibroblasts produced what are termed pro-collagen fibers, which are then insymmetrically assembled into collagen fibers, and form bundles within the dermis.
- Other molecules, such as decorin affect the function of the collagen.
- Collagen I, Ill, etc. there are various sub-types of collagen fibers such as Collagen I, Ill, etc., within the body. Collagen I comprises approximately 85% of the skin and Collagen III approximately 10%. However, in photoaged skin the amount of Collagen I decreases so the ratio of Collagen III/I is altered.
- MMP matrix metalloproteinases
- Fibroblasts also have important functions in wound healing with the removal of damaged structural ECM and the repair and production of (ECM).
- ECM structural ECM
- the Collagen I is degraded principally by MMP 1 (collagenase).
- MMP enzymes which degrade one or more of the structural proteins in the skin. While these degrading MMP enzymes serve an important role in removing damaged skin (for example, in wound healing), their activation and synthesis in increased quantities in normal skin helps contribute to the changes seen in both chronological and photoaging. Likewise, if the production of Collagen I is decreased or diminished this results in changes which are associated with chronologically or photoaged skin. Aging or senescent fibroblasts may exhibit decreased synthesis of Collagen I and increased synthesis of MMP 1. Similar changes are seen with UVA/UVB exposure. Other environmental agents may produce similar changes.
- Certain drugs, therapies, chemicals, active agents have been demonstrated to reversing the appearance of or phenotype of a chronologically aging or photoaging skin.
- Some topically applied agents serve as a physical or optical barrier either by reflection or absorption of ultraviolet light thus protecting the skin.
- enzymes that have been to shown actually repair the DNA dimers which are produced from UV damage.
- Other topically applied or oral or systemically agents have been shown to improve the appearance of the skin.
- One of the classic and well-known agents is a topical Vitamin A derivatives termed Retinoids.
- Numerous studies have demonstrated the ability to improve the appearance or phenotype of photoaged skin with the use of all-trans retinoic acid (RA). Many of the pathways involve the mechanism of action of RA and also Retinol (RO), Much of the mechanism of action in the cell signaling pathways through which RA appears to produce anti-aging effects.
- RA all-trans retinoic acid
- RO Retinol
- One of the goals of some current anti-aging therapies is to increase production of collagen in the ECM and the dermis of the skin. Some believe collagen I is the more desirable form of collagen to increase. There is some support for this since photoaged skin has less desirable visco elastic properties and this is thought in part to be due to the increased proportion of collagen Ill to collagen I. Other anti-aging approaches indicate that reducing the activity or production of the degrading enzymes in the ECM will similarly produce an anti-aging effect in the appearance of the skin. Doing a combination of both is even more beneficial. An analogy one might make is the production of new collagen I and that of freshly newly fallen snow. The amount of accumulation of the fresh snowfall is dependent both on the amount of snow that is fallen as well as the amount of the freshly fallen snow which then melts.
- an anti-aging therapy which stimulated new collagen production (newly fallen snow).
- new collagen production new collagen production
- a piece of black asphalt in a parking lot abuts a piece of warmer black asphalt adjoins a colder piece of concrete or frozen ground, while the amount of new snowfall is equal in both areas, the amount of accumulated snow is less was melted by the asphalt.
- an anti-aging therapy stimulates collagen I production, but does not diminish MMP 1 activity, the net increase in collagen I will be smaller than if the MMP 1 activity is also decreased.
- Non-ablative methods have typically been thermal in nature and through various means of laser light, intense pulsed light, radio frequency or microwave energy delivery then produced a thermal injury to the dermis.
- the present invention is directed to method and devices for improving the appearance of photoaged or damaged skin.
- Methods and devices involve the regulation of cell proliferation and gene expression of skin and other cells through photodynamic means such as photomodulation.
- One embodiment of the invention relates to reducing the undesirable effects and enhancing the beneficial effects of narrowband and wideband multichromatic electromagnetic radiation, as well as monochromatic radiation, emitted by sources including, but not limited to lasers (monochromatic and filtered, narrowband multichromatic), LED's (narrowband multichromatic), radio frequency, electromagnetic therapy or non ablative thermally mediated surgical procedures, etc.
- sources including, but not limited to lasers (monochromatic and filtered, narrowband multichromatic), LED's (narrowband multichromatic), radio frequency, electromagnetic therapy or non ablative thermally mediated surgical procedures, etc.
- LED photomodulation and other similar non-LED therapies may be used to enhance the desired effects or inhibit the undesirable one. This may be accomplished via means such as thermal injury to the skin which forces the expression of MMP and causing an increase structural proteins like collagen. LED light sources may also boost collagen while decreasing the upregulated MMP to produce a beneficial net effect. Such means generally quench the inflammatory processes that thermal therapies typically produce.
- One embodiment of the invention is directed to methods for both inhibiting, as well as reversing the appearance of photoaging (beauty maintenance or skin fitness) or chronological or environmentally damaged induced aging of human skin by application of photomodulation by, for example LED or other electromagnetic radiation treatment.
- the invention is directed to the regulation of cell proliferation of cells of the skin, and/or the regulation of gene expression in such cells.
- Another embodiment of the invention is directed to the various genotypes that characterize different phenotypes of aging skin and also a database comprising a collection or library of such phenotypes.
- the data base may comprise a plurality of genotypes identified from a variety of different individuals with the same disorder, or a variety of individuals with different disorders.
- Another embodiment of the invention is directed to photomodulation by light or electromagnetic radiation so as to effect cell proliferation and/or gene expression.
- electromagnetic radiation include ultrasound, radiowaves, micro rays, magnetic fields, any electrical stimulation that produces changes in the genotype or phenotype of aging skin, and combinations thereof.
- FIG. 1 is a chart which illustrates the RT-PCR expression of MMP-1 in cultured human fibroblasts.
- FIG. 2 is a chart which illustrates the RT-PCR expression of MMP-1 in cultured human fibroblasts under a variety of light exposure conditions.
- FIG. 3 is a chart which illustrates the RT-PCR expression of MMP-I in cultured human fibroblasts at varying energy fluences.
- FIG. 4 is a chart which illustrates the RT-PCR expression of cytochrome c oxidase 2 in cultured human fibroblasts after exposure to narrowband, multichromatic electromagnetic radiation.
- FIG. 5 is a chart which illustrates the RT-PCR expression of collagen I in cultured human fibroblasts after exposure to narrowband, multichromatic electromagnetic radiation.
- FIG. 6 is another chart which illustrates the RT-PCR expression of collagen I in cultured human fibroblasts after exposure to narrowband, multichromatic electromagnetic radiation.
- FIG. 7 is a chart which illustrates the RT-PCR expression of MMP-1, collagen I, and cytochrome c oxidase 2 in cultured human fibroblasts after exposure to narrowband, multichromatic electromagnetic radiation.
- FIG. 8 is another chart which illustrates the RT-PCR expression of collagen I in cultured human fibroblasts after exposure to narrowband, multichromatic electromagnetic radiation.
- FIG. 9 is another chart which illustrates the RT-PCR expression of collagen I in cultured human fibroblasts after exposure to narrowband, multichromatic electromagnetic radiation.
- FIG. 10 is a chart which illustrates the RT-PCR expression of cytochrome b in cultured human fibroblasts after exposure to narrowband, multichromatic electromagnetic radiation.
- FIG. 11 is a chart which illustrates the RT-PCR expression of cytochrome b oxidase I in cultured human fibroblasts after exposure to narrowband, multichromatic electromagnetic radiation.
- FIG. 12 is a chart which illustrates the RT-PCR expression of atpase6 in cultured human fibroblasts after exposure to narrowband, multichromatic electromagnetic radiation.
- FIG. 13 is a chart which illustrates the RT-PCR expression of cytochrome c oxidase Ill in cultured human fibroblasts after exposure to narrowband, multichromatic electromagnetic radiation.
- FIG. 14 is a chart which illustrates the RT-PCR expression of p53 in cultured human fibroblasts after exposure to narrowband, multichromatic electromagnetic radiation.
- FIG. 15 is a chart which illustrates the RT-PCR expression of MMP-1 in cultured human fibroblasts after exposure to narrowband, multichromatic electromagnetic radiation with varying energy fluence.
- FIG. 16 is a chart which illustrates the RT-PCR expression of collagen I in cultured human fibroblasts after exposure to narrowband, multichromatic electromagnetic radiation.
- FIG. 17 is a another chart which illustrates the RT-PCR expression of collagen I in cultured human fibroblasts after exposure to narrowband, multichromatic electromagnetic radiation employing various light cycle regimen and filters.
- FIG. 18 is a another chart which illustrates the RT-PCR expression of collagen I in cultured human fibroblasts after exposure to narrowband, multichromatic electromagnetic radiation employing various light cycle regimen and filters.
- FIG. 19 is another chart which illustrates the RT-PCR expression of MMP-1 in cultured human fibroblasts after exposure to narrowband, multichromatic electromagnetic radiation employing various light cycle regimen and filters.
- FIG. 20 is another chart which illustrates the RT-PCR expression of MMP-1 in cultured human fibroblasts after exposure to narrowband, multichromatic electromagnetic radiation employing various light cycle regimen and filters.
- FIG. 21 is a chart which illustrates the RT-PCR EGF expression in cultured human fibroblasts after exposure to electromagnetic radiation simulator solar radiation.
- FIG. 22 is a chart which illustrates the RT-PCR expression of collagen I in cultured human fibroblasts after exposure to electromagnetic radiation simulator solar radiation.
- FIG. 23 is a chart which illustrates the RT-PCR expression of cJun in cultured human fibroblasts after exposure to electromagnetic radiation simulator solar radiation.
- FIG. 24 is a chart which illustrates the RT-PCR expression of MMP-1 in cultured human fibroblasts after exposure to electromagnetic radiation simulator solar radiation.
- FIG. 25( a ) illustrates the specific extinction coefficients of various cytochromes at various wavelengths.
- FIG. 25( b ) illustrates specific extinction coefficients of the cytochromes of FIG. 25( a ) from 700 nm to 1000 nm.
- FIG. 26 illustrates specific extinction coefficients vs. wavelength.
- FIG. 27 shows the emission or spectral output of the LED with dominant visible and secondary infrared (IR) peaks and their relative intensity and shape.
- FIG. 28 shows the same LED emission with a selective infrared filter in place which reduces both the visible and IR output, but alters the relative ratio of visible to IR light as well as altering the shape of the IR spectral output curve.
- FIG. 29 shows the emission or spectral output of the LED with dominant visible and secondary infrared (IR) peaks and their relative intensity and shape.
- FIG. 30 shows the same LED emission with a selective infrared filter in place which reduces both the visible and IR output, but alters the relative ratio of visible to IR light as well as altering the shape of the IR spectral output curve.
- the present invention is directed to method and devices for the regulation of cell proliferation and gene expression and, in particular, the inhibition of photoaging of the skin, and the revival of necrotic cells.
- the invention is directed toward a system and method for rejuvenating cells in various stages of necrosis.
- Photoaging of the skin occurs through many mechanisms, including, for example, environmental factors such as tobacco smoke, exposure to the sun, and poor health, to name a few. These events can triggers an inflammatory process in the skin and the associated cellular mechanisms. There is also a more chronic low-level type of injury that does not produce a sunburn reaction, but which produces the changes of chronic photoaging. Chronological aging of the skin and photoaging and other environmentally induced changes share many or in some cases, all of the same pathways as UV induced photoaging of the skin. These pathways involve up and/or down regulation of cell proliferation and also alterations in the level of expression of many different types of genes.
- one embodiment of the invention is directed to identifying and correlating the phenotypic and genotypic expression characteristics of photoaging and other skin and cell-associated disorders. Once identified, correlated maps can be compiled and collected into a data base to allow for the rapid and efficient identification of similar disorders and conditions for the purpose of tailoring appropriate treatment. Further, once identified, treatment and appropriate intervention and prevention methods can be used to halt or even reverse the appearance and genotypic characteristics of photoaging. Thus, the invention is not directed to artificially hiding or covering up aspects associated with aging, but actually reversing the processes and mechanisms associated with aging-related phenomena.
- a further embodiment of the invention is directed to applying these same mechanisms and tools to other cells such as stem cells (completely undifferentiated cells) and progenitor cells (partially differentiated cells).
- stem cells completely undifferentiated cells
- progenitor cells partially differentiated cells.
- Methods to modulate cell proliferation and gene expression include exposure to electromagnetic radiation in an amount or dose that is sufficient to stimulate the desired effect (e.g. see U.S. Pat. Nos. 6,398,753, 5,837,224, and 6,130,254; and U.S. Patent Application Nos. 2002/0028185, 2001/0053347, 2003/0004556, 2003/0004499, and 2002/0123746, all of which are specifically and entirely incorporated by reference).
- exposure of skin to LED can stimulate or inhibit the expression of various gene products.
- photomodulation can be used in combination with certain oral agents (for systemic affects) or topical agents (for localized affects) (e.g. vitamin A, retin A, retinol), for a desired effect unachievable with either stimulant used individually.
- certain oral agents for systemic affects
- topical agents for localized affects
- e.g. vitamin A, retin A, retinol e.g. vitamin A, retin A, retinol
- the types of cells that can be affected include, but are not limited to skin cells (reversal of photoaging), nerve cells (disease prevention and treatment), stem cells (tissue reconstruction), cells of hair follicles (hair growth or inhibition), cells of the immune system including cells intimately involved with the process of inflammation (due to disease, infection, or congenital disorder), wound repair, and combinations thereof.
- Modulation can be achieved by exposing cells to electromagnetic radiation (e.g. photomodulation) such as, preferably, visible light, (e.g. purple, blue, green, yellow, orange, red), infrared radiation, ultraviolet light (UVA, UVB, UVA1, UVA2, or combinations thereof), or combinations of any.
- electromagnetic radiation e.g. photomodulation
- visible light e.g. purple, blue, green, yellow, orange, red
- infrared radiation ultraviolet light
- Preferred exposure strengths and exposure times are as set forth in the attachments hereto, but may include pulsed exposure
- Ultraviolet light injury triggers reactive oxygen species and a series of cell signaling events called kinase cascades.
- One of the final common pathway in the up and down regulation of fibroblast activity is through AP-1 which up regulates and increases the production of various MMP's including MMP 1 (collagenase 1 or interstitial collagenase synthesis), MMP 9 (gelatinases B) and MMP 3 (stromelysins 1).
- MMP 1 collagenase 1 or interstitial collagenase synthesis
- MMP 9 gelatinases B
- MMP 3 stromelysins 1).
- the production of these MMP enzymes results in the breakdown of collagen, elastin and ECM in the dermis of the skin. Simultaneously the actual production of collagen I and other structural proteins may be diminished or down regulated thus further accelerating the process.
- the aging of living cells, tissues and organs may be related to free radical exposure and oxidative stress.
- chronological aging results from a decrease antioxidant defense mechanisms while UV photoaging and other environmental stresses can be thought of as increasing oxidative stress.
- the net result of decreased antioxidant defense or increased oxidative stress is increase production of (ROS) or free radicals.
- SNPs Single nucleotide polymorphisms
- characterization of SNPs may allow prediction of whether a patient is more or less likely to develop a specific disease or tumor and thus take known preventative measures.
- Another possible application is the use of SNPs to screen individuals before placing them on a prescription drug to identify those individuals who might be more likely to develop serious side effects and thus avoid the use of that drug.
- Another potential novel use of SNPs is to identify the haplotype or patterns of SNPs, which are associate with, for example, chronological aging of the skin. Some individuals and families have reduced risk of skin cancers or simply look younger than their peers of the same age group and like backgrounds.
- a profile of SNPs can be developed that characterizes common factors associated with the phenotypic changes of aging skin (defined the SNP genotypic pattern that puts an individual at a greater risk of accelerate aging from increased oxidative stress from environmental agents). This allows for a treatment plan, which would have greater anti-aging benefits.
- TGF-B is a major cytokine for cell signaling and inhibits the growth of epidermal keratinocytes and stimulates the growth of thermal fibroblasts. It also induces synthesis and secretion of the major collagen elastin and inhibits the expression of MMP 1 and MMP 3.
- TGF-B's TGF-B 1, TBR I, TBR II, many of which are down regulated in aging skin cells.
- TGF-B is also activity altered in aging skin by binding with Decerin and when this combines with collagen affects the tinsel strength of skin as well as controlling the rate of collagen fiber formation.
- c Jun MRNA is doubled in activity and age human skin compared to young skin but c-fos was unchanged.
- MMP 2 is not regulated through AP 1.
- ERK activity is reduced in aging skin, but JNK activity is increased 3-4 times in aging skin.
- Environmental insults-damage can vary anatomically over a person's body.
- Increased MMP's result in reduced levels of ERK, cyclin D2 and type I and III pro collagen. This is part of the core genotype, phenotype stimulating a number of keratinocytes as well as decreasing c-gen activity and increasing ERK activity.
- Mitochondria and ATP production mechanisms can be modulated by electromagnetic radiation.
- LED light activates cell surface receptors via redox mediated in activation or a receptor type protein tyrosine phosphatase (RTPT).
- SAP stress activated pathways
- mitogen activated pathways compare and contrast SAP increase MMP and decreases pro collagen 1 and 2 if c Jun goes up.
- MAP stress activated pathways
- mitogen activated pathways compare and contrast SAP increase MMP and decreases pro collagen 1 and 2 if c Jun goes up.
- the MAP pathways activate ERK induced cyclins and promote cell growth so that PSAT's tend to increase or decrease protein production whereas the MAPS increase or decrease cell growth.
- Ras/MAP/AP-1 pathway plays a key role in response to wounding.
- FGFR1 contains sites in the promoter region and IL1 antagonist promoter.
- Antioxidant compounds also have anti-erythema sunscreen effect although they may not inhibit the increased MMP after UV exposure, lycopene is one of these.
- LED photomodulation can also be used to diminish sunburn activity and MMP levels were maxed about 24 hours later.
- Use a solar simulator to cause a one MED minimal erythema dose on the arm in two places on volunteers and treat one a couple times a day with the GW device and to reduce redness with the chromometer. Biopsy will show what happens when you treat them with GW after UV Inhibiting cytocrome P-450 breakdown of retinoids increases retinoid strength concentration.
- the invention includes the surprising discovery that multiple receptor-mediated pathways may be photomodulated in human or mammalian skin that lead to an expression of the genotype associated with a younger or more youthful or less aged skin both in appearance and structurally and functionally.
- infrared-a radiation induced MMP 1 is capable of producing MMP 1 by way of up regulation or activation of MAPK signaling pathway that is the activation of ERK 1/2 that the promoter region of the MMP 1 gene was activated by IRA without the production of heat, but that TIMP 1 was not increased.
- MMP-8 or elastase is increased with inflammatory reaction, which also involves AP I. And when NF-KB is increased it activates more of IL-1 and TNFa that discontinues the presence of continued inflammation.
- Fibroblasts sensor matrix surround them and when in contact with a matrix they tend to be less active produce little collagen, but when the presence of collagen breaks down products such as gelatin, they tend to produce more collagen if the inflammation persists. The collagen not only proliferates, but produces less scarring.
- Topical compounds that inhibit cytokines are indirect MMP inhibitors because if they block the pathway the signals MMP the essentially block this. The same is true for MMP regulation.
- Vitamin C can be topically applied to assemble stable collagen molecules. Collagen I and collagen III can be stimulated by topical of Vitamin C, whereas elastin, Fibrilin 1/2 are not affected nor is MMP 1, 2, and 9 affected. TIMP was increased, TIMP 2 was unchanged.
- Proteolytic degradation of ECM is an essential feature of repair and remodeling during continuous wound healing.
- Wound repair consists of narcotic or damaged tissue, cell and/or tissue migration, angiogenisis, remodeling of newly synthesized ECM, and cell growth factor regulations.
- MMP 1 and MMP 3 increase as well as MMP 2 and 9.
- MMP 13 in particular, for chronic wounds, but also acute.
- TIMP is also altered.
- MMP 1, 3, 9 are increased with UVB; increased elastin and fibrilian verscian; result in the formation of non functional elastin fibers and reduce skin elasticity and aging or photoaged skin.
- Collagen I is reduced, and UVA shows increased expression of MMP 1, 2, 3.
- single or multiple light sources may be used, to produce either a single dominant emissive wavelength, i.e., a narrowband multichromatic radiation, or multiple wavelengths (either monochromatic, narrowband multichromatic, wideband multichromatic, or combinations thereof).
- the single or multiple combinations may be applied either simultaneously or sequentially.
- a special IR filter may also be added to reduce the IR component of the radiation that the target skin or tissue is exposed to, as this is believed to unsymmetrically dampen the shape of the IR/850 curve.
- Treatment examples of such a device are shown in the attached drawing figures and illustrate that at 850 nm, there is believed to be a ‘dose dependent’ effect on fibroblasts.
- the ratio of yellow light to IR radiation in the radiation used for treatment has been found to have an effect on the overall performance of the present system. Relative amounts of each type of radiation are believed to be important, more so than the actual radiation level (provided that ablation does not occur). At about 4 mW/cm 2 for 590 nm and about 1 mW/cm 2 for the 850 nm (i.e., a 4:1 ratio of yellow to IR) has been found to produce good results. Mother factor to consider is the shape of the amplitude vs. wavelength curve for the IR component of the system.
- the ‘code’ refers to the pulse scheme for various treatment regimen. This includes various factors such as pulse length, interpulse delay, and pulse repetition.
- a treatment may comprise a pulse code of 250 msec “on” time, 100 msec “off” time (or dark period), and 100 pulses. This produces a total energy fluence, in J/cm2, of 25 seconds times the power output level of the emitters.
- the present invention is also related to a method and apparatus for treating sunburn and other sun-related photoeffects on human or mammalian skin.
- One approach is to use Retin A for prior to sun exposure and research is being conducted using vitamins C, E, and other antioxidants topically.
- Another approach being tried is the use of the antioxidant Lycopene, administered orally, to quench some of inflammation from sunburn.
- the present invention shows great improvement of such treatment methods, however.
- the solar simulator of the present invention is, in some ways, a model for other wound healings.
- the present invention employs a treatment that simulates sunlight broken down into its component parts.
- the UVA 1 portion is used in some embodiments, but there is UVB and combinations of UVA and UVR that are more oncogenic.
- UV, and in particular UVA 1 causes skin sagging and photoaging, changes to the dermal matrix and structural proteins, and upregulates MMPs.
- UV radiation also causes the upregulation of inflammatory pathways such as IL1, IL6 and NFkB. These pathways are known to affect aging and other sun-related skin disorders and environmental damage, such as smoking, pollution, drugs, diseases, thermal injuries, other wounds.
- the present invention is believed to inhibit or reverse the effects of photoaging and other skin disorders by reversing the direction of gene up/down regulation from the unfavorable and destructive directions caused by the effects of the solar simulator UVA1 for things like collagen, MMP1, cJun which is important related to MMP1, IL/interleukins in inflammatory pathway, and cytochromes.
- the attached examples describe the use of the present system for illustrative treatments.
- the systems and methods of the present invention may be used in combination with various wound dressings like bandage strips modified to have a transparent covering, so that the desired spectra of photomodulation by LED or other light is transmitted to the wounded area of the skin or target tissue.
- One embodiment includes ‘trap door’ to permit the periodic inhibition of light transmission.
- the opening or translucent/transparent portion of the bandage may comprise an IR filter, as well. In instances where it is undesirable to include an opening as part of the bandage or wound dressing, the size of LED's and other light sources makes it possible to include a light source within the bandage.
- Such a source could be powered from a small battery and include means for having the light source automatically or manually apply treatment at regular intervals and according to a variety of preset codes (for example, a dressed chemical burn may require a different code than a cut or electrical burn).
- various topical compositions for enhancing the penetration of the light through the skin or target tissue can be included in the dressing or bandage or applied to the skin or target tissue prior to covering the affected skin with the bandage or dressing.
- a light source within the bandage may also be coded to ‘release’ or to ‘activate’ substances or delivery vehicles for substances so that oxygen, antibacterial, antiviral, anti fungal, etc., or other agents released. Combinations of such compositions may be used as well.
- Another application would allow for the treatment of blood outside of the body (extracorporeally, in a phoresis device for example).
- the blood may be run through banks of arrays of LED, or other light or EMR, and then photomodulated either directly or by an agent that was photoactivatable, or both, to stimulate the immune system, treat disease, etc.
- the present system and method may also be used for retinal and other eye treatments, alone or along with antioxidant eyedrop-type medications, bioengineered peptides, and growth factors.
- Antioxidant eyedrops include, but are not limited to glutathione, vitamin C, vitamin E, catalase, ubiquinone, idebenone, etc.
- adipocytes for fat reduction, cellulite, etc. may be accomplished using light sources in the range of about 850-950 nm and 1000-1100 nm.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Biophysics (AREA)
- Surgery (AREA)
- Otolaryngology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Radiation-Therapy Devices (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
A method including photomodulating mammalian tissue with more than one light source of narrowband, multi chromatic electromagnetic radiation, wherein at least one light source emits radiation at a wavelength corresponding to yellow light and at least one light source emits radiation corresponding to infra-red light, wherein the ratio of the intensity of yellow light to infra-red light is about 4:1.
Description
- This application is a divisional application of and claims the benefit of priority under 35 U.S.C. §120 from U.S. application Ser. No. 12/550,464, filed Aug. 31, 2009, which is a continuation application of U.S. application Ser. No. 10/903,483, filed Aug. 2, 2004, now abandoned, which is a non-provisional application of U.S. Provisional Application No. 60/491,277, filed Jul. 31, 2003, the contents of each of which is hereby incorporated by reference in their entirety.
- 1. Field of the Invention
- This invention relates to method and devices for the photodynamic regulation of cell proliferation and gene expression. In particular, the invention relates to the reducing, reversing, and/or diminishing the effects of sunburn, thermal burns, chemical burns, radiation burns, various types of wounds, such as traumatic, surgical, laser, chemical peel, cosmetic surgery, warfare agents or injuries, freezing, hypoxia, vascular insufficiency, bruising, chronic ulcers, etc., allergic reactions or contact dermatitis, and various inflammatory diseases.
- 2. Description of the Background
- Chronological aging, “photo-aging”, i.e., the aging of skin caused by exposure to natural and synthetic light sources, disease, and trauma all bring about changes in the appearance of human and mammalian skin as well as changes in the structure and function of the skin. All living cells, tissues and organs also undergo changes associated with chronological aging, bruising, photo-aging, disease, and trauma. Since the human skin is an organ that is highly visible, the changes associated with these conditions are readily apparent and visible. These changes are reflections of the underlying structural and functional changes.
- The most widely appreciated form of skin aging is that which is produced by over exposure and repeated chronic exposure to sunlight and is generally termed photoaging. More specifically certain portions of the ultraviolet A (UVA) and ultraviolet B (UVB) and have been determined to be the principal causative factors of what are associated with photoaging.
- For many years it was thought that photoaging occurred through a different mechanism of action or and was somehow different than chronological aging. However, more recently it appears that photoaging and chronological aging may share similar, if not identical pathways.
- Solar radiation is composed of ultraviolet (LTV), visible and infrared, light. Current conventions divide IJV radiation into UVA (320-400 nm), UUB (290-320 nm) and UVC (<290 nm). UVC radiation is blocked by ozone in the stratosphere and does not reach the earth's surface, but can be generated by germicidal lamps and other machinery. UVA and UVB sunlight do reach the earth and are believed to be the principal agents of photoaging. UVA radiation is further subdivided into
UVA 1 andUVA 2. While UVB has been believed to be the primary agent for photoaging, it is now appreciated that certain wavelength ranges within the UVA rays also contribute to changes associated with photoaging. - Acute environmental injuries include sunburn from UV light and other thermal, chemical, and other types of burns or burn-like injuries. These type of injuries produce not only damaged cells, but dying cells. Damaged cells may either repair the damage and return to normal, repair the damage imperfectly and produce an abnormal or sub-optimally functioning cell, or the cells may die. In the case of sunburn chronic sun-damage accumulates damaged and imperfectly repaired cells to produce what might be termed ‘solar scars’ but we more commonly think of these as ‘wrinkles’. That is a wrinkle is really the result of accumulation of imperfectly repaired cell damage. Likewise the brown ‘liver’ or ‘age spots’ that are common as one ages and photoages are similarly damage to the pigment cells or melanocytes.
- Acute UV injury or sunburn produces dying cells in the upper skin layer or epidermis called ‘sunburn cells’. Counting sunburn cells is a classic scientific method to quantify the severity of damage to these keratinocyte cells. Therapies which reduce the number of sunburn cells are considered beneficial to diminishing the severity of the injury or repairing or reversing the injury. More generally speaking damaged cells which might recover or die are termed ‘apoptotic’ cells and those cells which are irreversibly damaged and will die are termed ‘necrotic’ cells. Treatments which can turn necrotic cells into living cells would be considered treatments which ‘rescue’ or ‘revive’ the cells which are destined for death. Such treatments and therapies would have great importance in treating not only acute sunburn, but sub-acute sun damage that leads to accumulated chronic damage. The ability to ‘rescue’ dying cells in wounds, burns, etc would have a powerful impact on healing time, scarring or lack thereof, infection risk, and even survival of entire organs or organisms. The pertinent arts have, heretofore, been unable to produce a system or method for reviving or rescuing necrotic cells or those in advanced stages of necrosis.
- UVA and UVB light exposure to human skin triggers a series of molecular events including the induction of reactive oxygen species (ROS) in the skin. Through a series of cell signaling events collagen production is down regulated and various enzymes known to degrade structural proteins in the skin up-regulated. The net result of this is a decrease in collagen and the production of wound. The skin's reaction to UVA or UVB (or combined) wounding is to repair the wound through the skins wound healing mechanism. Typically these wound repair mechanisms are imperfect which is considered by many to be a solar scar. After many years of the UVA or UVB wounding of the skin, chronic solar scarring develops which manifests itself in the visible phenotypic changes termed photoaging, which might also be considered the visible outward evidence of solar scars.
- Photoaging of the skin may occur through acute injury at higher levels, such as what one associates with sunburn. This triggers an inflammatory process in the skin and the associated cellular mechanisms. There is also a more chronic low-level type of injury that does not produce a sunburn reaction, but which produces the changes of chronic photoaging. Other processes, which are known to decrease collagen production and increase collagen-dissolving enzymes, such as tobacco smoking, also are associated with changes that visibly appear, similar to the photoaging from UVA/UVB light. This can be seen strikingly in photographs of identical twins wherein only one twin smoked tobacco for many years.
- UVB radiation in sufficient doses produces reddening or sun burning of the skin. The threshold level is typically described as minimal erythema′ dose (MED), typically produced by 290-300 nm UVB wavelengths. As the wavelengths increase they become much less likely to produce the redness and burning reactions and indeed wavelengths of 320 nm are about 100 times as powerful as wavelengths of 340 nm approximately 100 times less powerful than the 290-300 nm range of producing erythema and sunburns. The total UVB exposure is more related to the appearance of photoaging and sunburns are more likely to trigger malignant changes in the skin such as malignant melanoma. In contrast, UVA radiation can produce redness, but also produced tanning and these are the wavelengths typically used for the so-called tanning beds. UVA radiation is a longer wavelength and is proportionately greater in the early morning and late afternoon and the UUB rays, which are typically most predominant and intense at the midday summer sun time exposure period, UVA radiation may also penetrate certain sun blocks mid certain sunscreens and also window glass on automobiles, thus accounting for the frequently observed greater wrinkling, brown pigmentation and redness and overall aged appearance on the left side of the face than the right in patients who occupationally or recreationally spend considerable time driving a left hand drive motor vehicle.
- In sunny countries with fair complexioned populations, such as Australia, where right hand drive motor vehicles are used, these changes are seen typically seen on the right side of the face. The patterns of photoaging are determined by which areas of the body are anatomically are more chronically exposed to sunlight. Thus, the face, neck, back of hands, upper chest, lower arms, lower legs and depending on hair styling and density, ears and balding areas manifest the greatest photoaging changes.
- The chronological changes and photoaging changes typically are manifest by fine lines and wrinkling of the skin. A coarser, crepey texture to the skin, skin laxity and skin sagging, uneven pigmentation, brown splotchy pigment, loss of skin tone, texture and radiancy, bruising and sallowness. The skin is composed of several layers, the outermost layer is called the stratamocornium (SC), next layer is the epidermis (EPI), and underneath the epidermis lies the dermis (DER). The outer SC serves primarily a barrier function to protect the skin from environmental exposure and also to help minimize water loss from the skin. The epidermis serves many important and diverse roles as does the dermis. The dermis contains the principal structural proteins of the skin. These proteins are collagen, elastin and ground substance. They are manufactured by the fibroblast cells within the dermis. Fibroblast cells control the activity to produce these proteins as regulated by a complex and relatively well defined series of cell receptors and cell signaling mechanisms.
- The proliferation of these cells is also an important activity. For example, the dermis also contains blood vessels, nerve fibers, oil and sweat glands, hair follicles and many other important components. There is a remarkably complex inner communication through cell signaling in the cells of the skin. Fibroblasts produced what are termed pro-collagen fibers, which are then insymmetrically assembled into collagen fibers, and form bundles within the dermis. Other molecules, such as decorin affect the function of the collagen. There are various sub-types of collagen fibers such as Collagen I, Ill, etc., within the body. Collagen I comprises approximately 85% of the skin and Collagen III approximately 10%. However, in photoaged skin the amount of Collagen I decreases so the ratio of Collagen III/I is altered.
- There are also a variety of enzymes termed matrix metalloproteinases (MMP) which play important roles in aging skin. Fibroblasts also have important functions in wound healing with the removal of damaged structural ECM and the repair and production of (ECM). The Collagen I is degraded principally by MMP 1 (collagenase). There are a variety of MMP enzymes, which degrade one or more of the structural proteins in the skin. While these degrading MMP enzymes serve an important role in removing damaged skin (for example, in wound healing), their activation and synthesis in increased quantities in normal skin helps contribute to the changes seen in both chronological and photoaging. Likewise, if the production of Collagen I is decreased or diminished this results in changes which are associated with chronologically or photoaged skin. Aging or senescent fibroblasts may exhibit decreased synthesis of Collagen I and increased synthesis of
MMP 1. Similar changes are seen with UVA/UVB exposure. Other environmental agents may produce similar changes. - Certain drugs, therapies, chemicals, active agents have been demonstrated to reversing the appearance of or phenotype of a chronologically aging or photoaging skin. Some topically applied agents serve as a physical or optical barrier either by reflection or absorption of ultraviolet light thus protecting the skin. There are also enzymes that have been to shown actually repair the DNA dimers which are produced from UV damage. Other topically applied or oral or systemically agents have been shown to improve the appearance of the skin. One of the classic and well-known agents is a topical Vitamin A derivatives termed Retinoids. Numerous studies have demonstrated the ability to improve the appearance or phenotype of photoaged skin with the use of all-trans retinoic acid (RA). Many of the pathways involve the mechanism of action of RA and also Retinol (RO), Much of the mechanism of action in the cell signaling pathways through which RA appears to produce anti-aging effects.
- One of the goals of some current anti-aging therapies is to increase production of collagen in the ECM and the dermis of the skin. Some believe collagen I is the more desirable form of collagen to increase. There is some support for this since photoaged skin has less desirable visco elastic properties and this is thought in part to be due to the increased proportion of collagen Ill to collagen I. Other anti-aging approaches indicate that reducing the activity or production of the degrading enzymes in the ECM will similarly produce an anti-aging effect in the appearance of the skin. Doing a combination of both is even more beneficial. An analogy one might make is the production of new collagen I and that of freshly newly fallen snow. The amount of accumulation of the fresh snowfall is dependent both on the amount of snow that is fallen as well as the amount of the freshly fallen snow which then melts. Thus one could envision an anti-aging therapy which stimulated new collagen production (newly fallen snow). When a piece of black asphalt in a parking lot abuts a piece of warmer black asphalt adjoins a colder piece of concrete or frozen ground, while the amount of new snowfall is equal in both areas, the amount of accumulated snow is less was melted by the asphalt. If an anti-aging therapy stimulates collagen I production, but does not diminish
MMP 1 activity, the net increase in collagen I will be smaller than if theMMP 1 activity is also decreased. - Historically there have been many approaches to restoring a youthful appearance to human skin for achieving anti-aging or age reversal therapies. Most methods utilize some form of triggering the body's own wound healing mechanism. The more destructive and traumatic methods use chemicals to peel off the stratum cornium epidermis and often a portion of the dermis or they mechanically abraded by sand papering or dermabrating or more recently high-energy thermal lasers have been used to vaporize or coagulate the skin. These methods have a prolonged and painful wounding period and require wound care and patients typically must limit their daily social and business activities during the wound-healing phase. Subsequently the skin undergoes months or years an on going wound healing and wound remodeling process whereby damage is repaired and new structural proteins in skin are generated. These treatments typically amount to trying to produce a controlled entry to the skin and proving the wound care environment that minimizes the risk of scarring. These methods are notoriously known for producing many problems and sometimes even disfiguring scarring or catastrophic pigment changes in the skin. However, properly performed and with good wound care, many people achieved significant and sometimes dramatic anti-aging effects. Other gentler methods have become more popular in recent years which involve the classic plastic surgery lifting procedures and newer procedures termed non-ablative where the outer stratum eornium and epidermis are not removed or blated from the skin, but are by various means and methods protected and left in tact. Non-ablative methods have typically been thermal in nature and through various means of laser light, intense pulsed light, radio frequency or microwave energy delivery then produced a thermal injury to the dermis. The theory behind these therapies is that this injury will result in a net increase in the desirable structural proteins, while not triggering, worsening, scarring or other complications. Results are occasionally traumatic but have been extremely variable with this therapy. The variability in individuals wound healing repair mechanism and the overall health of their body and skin and many other factors contribute to this variability.
- There are various topical agents that have been developed for anti-aging purposes such as Retinoic acid, topical Vitamin C, topical Vitamin B and other antioxidant and other antiwrinkle creams and lotions. Many of these are well defined. Additional topical compositions, cosmeceuticals, etc. are disclosed in applicant's copending application serial number U.S. Ser. No. 09/899,894, entitled “Method and Apparatus for the Photomodulation of Living Cells”, filed Jun. 29, 2001, which is hereby incorporated by reference in its entirety. Further, methods for enhancing the penetration of such composition into the skin using ultrasound radiation are described in U.S. Pat. No. 6,030,374, and U.S. Pat. No. 6,398,753, each of which is hereby incorporated by reference in its entirety. Use of such compositions for wound treatment, acne reduction, and other dermatological conditions is described in applicant's copending application Ser. No. 09/933,870, filed Aug. 22, 2001, which is also incorporated by reference herein in its entirety. Additional discussion of the related art is described in applications copending application Ser. No. 10/119,772, filed Apr. 11, 2002, and 60/461,512, filed Apr. 10, 2003, which are also incorporated by reference herein in their entirety.
- There is a need to improve the appearance of chronologically aged, photoaged, or environmentally damaged skin, as well as skin that has been damaged by disease or trauma, but without producing the risk, complications, recovery time, pain, discomfort, wound care or other side effects traditionally associated with surgical, chemical, electromagnetic radiation and other types of therapies.
- As embodied and broadly described herein, the present invention is directed to method and devices for improving the appearance of photoaged or damaged skin. Methods and devices involve the regulation of cell proliferation and gene expression of skin and other cells through photodynamic means such as photomodulation.
- One embodiment of the invention relates to reducing the undesirable effects and enhancing the beneficial effects of narrowband and wideband multichromatic electromagnetic radiation, as well as monochromatic radiation, emitted by sources including, but not limited to lasers (monochromatic and filtered, narrowband multichromatic), LED's (narrowband multichromatic), radio frequency, electromagnetic therapy or non ablative thermally mediated surgical procedures, etc. For example, LED photomodulation and other similar non-LED therapies may be used to enhance the desired effects or inhibit the undesirable one. This may be accomplished via means such as thermal injury to the skin which forces the expression of MMP and causing an increase structural proteins like collagen. LED light sources may also boost collagen while decreasing the upregulated MMP to produce a beneficial net effect. Such means generally quench the inflammatory processes that thermal therapies typically produce.
- One embodiment of the invention is directed to methods for both inhibiting, as well as reversing the appearance of photoaging (beauty maintenance or skin fitness) or chronological or environmentally damaged induced aging of human skin by application of photomodulation by, for example LED or other electromagnetic radiation treatment. Preferably, the invention is directed to the regulation of cell proliferation of cells of the skin, and/or the regulation of gene expression in such cells.
- Another embodiment of the invention is directed to the various genotypes that characterize different phenotypes of aging skin and also a database comprising a collection or library of such phenotypes. The data base may comprise a plurality of genotypes identified from a variety of different individuals with the same disorder, or a variety of individuals with different disorders.
- Another embodiment of the invention is directed to photomodulation by light or electromagnetic radiation so as to effect cell proliferation and/or gene expression. Examples of different types of electromagnetic radiation include ultrasound, radiowaves, micro rays, magnetic fields, any electrical stimulation that produces changes in the genotype or phenotype of aging skin, and combinations thereof.
- Other embodiments and advantages of the invention are set forth in part in the description, which follows, and in part, may be obvious from this description, or may be learned from the practice of the invention.
-
FIG. 1 is a chart which illustrates the RT-PCR expression of MMP-1 in cultured human fibroblasts. -
FIG. 2 is a chart which illustrates the RT-PCR expression of MMP-1 in cultured human fibroblasts under a variety of light exposure conditions. -
FIG. 3 is a chart which illustrates the RT-PCR expression of MMP-I in cultured human fibroblasts at varying energy fluences. -
FIG. 4 is a chart which illustrates the RT-PCR expression ofcytochrome c oxidase 2 in cultured human fibroblasts after exposure to narrowband, multichromatic electromagnetic radiation. -
FIG. 5 is a chart which illustrates the RT-PCR expression of collagen I in cultured human fibroblasts after exposure to narrowband, multichromatic electromagnetic radiation. -
FIG. 6 is another chart which illustrates the RT-PCR expression of collagen I in cultured human fibroblasts after exposure to narrowband, multichromatic electromagnetic radiation. -
FIG. 7 is a chart which illustrates the RT-PCR expression of MMP-1, collagen I, andcytochrome c oxidase 2 in cultured human fibroblasts after exposure to narrowband, multichromatic electromagnetic radiation. -
FIG. 8 is another chart which illustrates the RT-PCR expression of collagen I in cultured human fibroblasts after exposure to narrowband, multichromatic electromagnetic radiation. -
FIG. 9 is another chart which illustrates the RT-PCR expression of collagen I in cultured human fibroblasts after exposure to narrowband, multichromatic electromagnetic radiation. -
FIG. 10 is a chart which illustrates the RT-PCR expression of cytochrome b in cultured human fibroblasts after exposure to narrowband, multichromatic electromagnetic radiation. -
FIG. 11 is a chart which illustrates the RT-PCR expression of cytochrome b oxidase I in cultured human fibroblasts after exposure to narrowband, multichromatic electromagnetic radiation. -
FIG. 12 is a chart which illustrates the RT-PCR expression of atpase6 in cultured human fibroblasts after exposure to narrowband, multichromatic electromagnetic radiation. -
FIG. 13 is a chart which illustrates the RT-PCR expression of cytochrome c oxidase Ill in cultured human fibroblasts after exposure to narrowband, multichromatic electromagnetic radiation. -
FIG. 14 is a chart which illustrates the RT-PCR expression of p53 in cultured human fibroblasts after exposure to narrowband, multichromatic electromagnetic radiation. -
FIG. 15 is a chart which illustrates the RT-PCR expression of MMP-1 in cultured human fibroblasts after exposure to narrowband, multichromatic electromagnetic radiation with varying energy fluence. -
FIG. 16 is a chart which illustrates the RT-PCR expression of collagen I in cultured human fibroblasts after exposure to narrowband, multichromatic electromagnetic radiation. -
FIG. 17 is a another chart which illustrates the RT-PCR expression of collagen I in cultured human fibroblasts after exposure to narrowband, multichromatic electromagnetic radiation employing various light cycle regimen and filters. -
FIG. 18 is a another chart which illustrates the RT-PCR expression of collagen I in cultured human fibroblasts after exposure to narrowband, multichromatic electromagnetic radiation employing various light cycle regimen and filters. -
FIG. 19 is another chart which illustrates the RT-PCR expression of MMP-1 in cultured human fibroblasts after exposure to narrowband, multichromatic electromagnetic radiation employing various light cycle regimen and filters. -
FIG. 20 is another chart which illustrates the RT-PCR expression of MMP-1 in cultured human fibroblasts after exposure to narrowband, multichromatic electromagnetic radiation employing various light cycle regimen and filters. -
FIG. 21 is a chart which illustrates the RT-PCR EGF expression in cultured human fibroblasts after exposure to electromagnetic radiation simulator solar radiation. -
FIG. 22 is a chart which illustrates the RT-PCR expression of collagen I in cultured human fibroblasts after exposure to electromagnetic radiation simulator solar radiation. -
FIG. 23 is a chart which illustrates the RT-PCR expression of cJun in cultured human fibroblasts after exposure to electromagnetic radiation simulator solar radiation. -
FIG. 24 is a chart which illustrates the RT-PCR expression of MMP-1 in cultured human fibroblasts after exposure to electromagnetic radiation simulator solar radiation. -
FIG. 25( a) illustrates the specific extinction coefficients of various cytochromes at various wavelengths. -
FIG. 25( b) illustrates specific extinction coefficients of the cytochromes ofFIG. 25( a) from 700 nm to 1000 nm. -
FIG. 26 illustrates specific extinction coefficients vs. wavelength. -
FIG. 27 shows the emission or spectral output of the LED with dominant visible and secondary infrared (IR) peaks and their relative intensity and shape. -
FIG. 28 shows the same LED emission with a selective infrared filter in place which reduces both the visible and IR output, but alters the relative ratio of visible to IR light as well as altering the shape of the IR spectral output curve. -
FIG. 29 shows the emission or spectral output of the LED with dominant visible and secondary infrared (IR) peaks and their relative intensity and shape. -
FIG. 30 shows the same LED emission with a selective infrared filter in place which reduces both the visible and IR output, but alters the relative ratio of visible to IR light as well as altering the shape of the IR spectral output curve. - As embodied and broadly described herein, the present invention is directed to method and devices for the regulation of cell proliferation and gene expression and, in particular, the inhibition of photoaging of the skin, and the revival of necrotic cells. As well, the invention is directed toward a system and method for rejuvenating cells in various stages of necrosis.
- Photoaging of the skin occurs through many mechanisms, including, for example, environmental factors such as tobacco smoke, exposure to the sun, and poor health, to name a few. These events can triggers an inflammatory process in the skin and the associated cellular mechanisms. There is also a more chronic low-level type of injury that does not produce a sunburn reaction, but which produces the changes of chronic photoaging. Chronological aging of the skin and photoaging and other environmentally induced changes share many or in some cases, all of the same pathways as UV induced photoaging of the skin. These pathways involve up and/or down regulation of cell proliferation and also alterations in the level of expression of many different types of genes.
- It was surprisingly discovered that, this combination of regulation of cell proliferation and regulation of gene expression, is responsible for photoaging of the skin and other cells and tissues, and thus, photoaging could be reversed or at least ameliorated by affecting these same processes. Accordingly, one embodiment of the invention is directed to identifying and correlating the phenotypic and genotypic expression characteristics of photoaging and other skin and cell-associated disorders. Once identified, correlated maps can be compiled and collected into a data base to allow for the rapid and efficient identification of similar disorders and conditions for the purpose of tailoring appropriate treatment. Further, once identified, treatment and appropriate intervention and prevention methods can be used to halt or even reverse the appearance and genotypic characteristics of photoaging. Thus, the invention is not directed to artificially hiding or covering up aspects associated with aging, but actually reversing the processes and mechanisms associated with aging-related phenomena.
- A further embodiment of the invention is directed to applying these same mechanisms and tools to other cells such as stem cells (completely undifferentiated cells) and progenitor cells (partially differentiated cells). By altering the cell cycle, cell proliferation, and/or gene expression characteristics of these cells along defined parameters, it is possible to determine differentiation pathways and to create or recreate cells, tissues and other cell structures for disease therapy and prevention, and wound healing.
- Methods to modulate cell proliferation and gene expression include exposure to electromagnetic radiation in an amount or dose that is sufficient to stimulate the desired effect (e.g. see U.S. Pat. Nos. 6,398,753, 5,837,224, and 6,130,254; and U.S. Patent Application Nos. 2002/0028185, 2001/0053347, 2003/0004556, 2003/0004499, and 2002/0123746, all of which are specifically and entirely incorporated by reference). For example, exposure of skin to LED can stimulate or inhibit the expression of various gene products. These same methods can be used to cause stimulation or inhibition of cell proliferation and cell cycle modulation in these cell populations. Further, photomodulation can be used in combination with certain oral agents (for systemic affects) or topical agents (for localized affects) (e.g. vitamin A, retin A, retinol), for a desired effect unachievable with either stimulant used individually.
- The types of cells that can be affected include, but are not limited to skin cells (reversal of photoaging), nerve cells (disease prevention and treatment), stem cells (tissue reconstruction), cells of hair follicles (hair growth or inhibition), cells of the immune system including cells intimately involved with the process of inflammation (due to disease, infection, or congenital disorder), wound repair, and combinations thereof. Modulation can be achieved by exposing cells to electromagnetic radiation (e.g. photomodulation) such as, preferably, visible light, (e.g. purple, blue, green, yellow, orange, red), infrared radiation, ultraviolet light (UVA, UVB, UVA1, UVA2, or combinations thereof), or combinations of any. Preferred exposure strengths and exposure times are as set forth in the attachments hereto, but may include pulsed exposures, continuous and periodic exposures.
- Ultraviolet light injury triggers reactive oxygen species and a series of cell signaling events called kinase cascades. One of the final common pathway in the up and down regulation of fibroblast activity is through AP-1 which up regulates and increases the production of various MMP's including MMP 1 (
collagenase 1 or interstitial collagenase synthesis), MMP 9 (gelatinases B) and MMP 3 (stromelysins 1). The production of these MMP enzymes results in the breakdown of collagen, elastin and ECM in the dermis of the skin. Simultaneously the actual production of collagen I and other structural proteins may be diminished or down regulated thus further accelerating the process. - The aging of living cells, tissues and organs may be related to free radical exposure and oxidative stress. To apply this model to aging skin, chronological aging results from a decrease antioxidant defense mechanisms while UV photoaging and other environmental stresses can be thought of as increasing oxidative stress. The net result of decreased antioxidant defense or increased oxidative stress is increase production of (ROS) or free radicals.
- Increased ROS production in the skin stimulates cell signaling or signals transduction pathways, which produce altered gene activity. Damage to structural proteins (e.g. damage, disruption and fragmentation of collagen caused by UV light) alters proteins, structure and function which in turn changes cell signaling and may alter gene activity. Another possible outcome of increased ROS production is the production of DNA mutations, which then alters gene structure and thus may alter the normal structure and function of cells. Much of the variation in the human state, as far as disease and response to environmental insults may be mediated by relatively small differences in the genetic make-up from one individual to the next. Single nucleotide polymorphisms (SNPs) are currently being very actively investigated as a means of identifying and potentially predicting the differences in biological responses of humans and other animals. For example, characterization of SNPs may allow prediction of whether a patient is more or less likely to develop a specific disease or tumor and thus take known preventative measures. Another possible application is the use of SNPs to screen individuals before placing them on a prescription drug to identify those individuals who might be more likely to develop serious side effects and thus avoid the use of that drug. Another potential novel use of SNPs is to identify the haplotype or patterns of SNPs, which are associate with, for example, chronological aging of the skin. Some individuals and families have reduced risk of skin cancers or simply look younger than their peers of the same age group and like backgrounds. A profile of SNPs can be developed that characterizes common factors associated with the phenotypic changes of aging skin (defined the SNP genotypic pattern that puts an individual at a greater risk of accelerate aging from increased oxidative stress from environmental agents). This allows for a treatment plan, which would have greater anti-aging benefits.
- TGF-B is a major cytokine for cell signaling and inhibits the growth of epidermal keratinocytes and stimulates the growth of thermal fibroblasts. It also induces synthesis and secretion of the major collagen elastin and inhibits the expression of
MMP 1 andMMP 3. There are multiple TGF-B's, TGF-B 1, TBR I, TBR II, many of which are down regulated in aging skin cells. TGF-B is also activity altered in aging skin by binding with Decerin and when this combines with collagen affects the tinsel strength of skin as well as controlling the rate of collagen fiber formation. c Jun MRNA is doubled in activity and age human skin compared to young skin but c-fos was unchanged.MMP 2 is not regulated throughAP 1. ERK activity is reduced in aging skin, but JNK activity is increased 3-4 times in aging skin. Environmental insults-damage can vary anatomically over a person's body. These methods allow for rejuvenating human skin including the steps of simultaneously preventing collagen degradation while also stimulating the formation of new collagen in aging human skin. - Increased MMP's result in reduced levels of ERK, cyclin D2 and type I and III pro collagen. This is part of the core genotype, phenotype stimulating a number of keratinocytes as well as decreasing c-gen activity and increasing ERK activity.
- A system of sunscreens, topical oil and antioxidants, topical oil and photomodulated ECM stimulation and MMP and MMP inhibition and various combinations and mixtures of the above. Inhibiting c-gen formation also inhibits formation AP-I and thus diminishes MMP's, inducing the proliferation of keratinocytes and fibroblasts.
- Mitochondria and ATP production mechanisms (e.g. cytochrome expression) can be modulated by electromagnetic radiation. LED light activates cell surface receptors via redox mediated in activation or a receptor type protein tyrosine phosphatase (RTPT). SAP (stress activated pathways) verses mitogen activated pathways compare and contrast SAP increase MMP and decreases
pro collagen - While not wishing to be constrained to a particular theory of operation, the invention includes the surprising discovery that multiple receptor-mediated pathways may be photomodulated in human or mammalian skin that lead to an expression of the genotype associated with a younger or more youthful or less aged skin both in appearance and structurally and functionally.
- Reference to infrared-a radiation induced
MMP 1. Infrared is capable of producingMMP 1 by way of up regulation or activation of MAPK signaling pathway that is the activation ofERK 1/2 that the promoter region of theMMP 1 gene was activated by IRA without the production of heat, but thatTIMP 1 was not increased. MMP-8 or elastase is increased with inflammatory reaction, which also involves AP I. And when NF-KB is increased it activates more of IL-1 and TNFa that discontinues the presence of continued inflammation. - Fibroblasts sensor matrix surround them and when in contact with a matrix they tend to be less active produce little collagen, but when the presence of collagen breaks down products such as gelatin, they tend to produce more collagen if the inflammation persists. The collagen not only proliferates, but produces less scarring.
- Topical compounds that inhibit cytokines are indirect MMP inhibitors because if they block the pathway the signals MMP the essentially block this. The same is true for MMP regulation. Regarding nutraceuticals, Vitamin C can be topically applied to assemble stable collagen molecules. Collagen I and collagen III can be stimulated by topical of Vitamin C, whereas elastin,
Fibrilin 1/2 are not affected nor isMMP TIMP 2 was unchanged. - Proteolytic degradation of ECM is an essential feature of repair and remodeling during continuous wound healing. Wound repair consists of narcotic or damaged tissue, cell and/or tissue migration, angiogenisis, remodeling of newly synthesized ECM, and cell growth factor regulations. During
wound repair MMP 1 andMMP 3 increase as well asMMP 2 and 9. MMP 13, in particular, for chronic wounds, but also acute. TIMP is also altered.MMP MMP - Disease states-systemic sclaraderma skin fibroblasts produced
less MMP 1 andMMP 3 andmore TIMP 1 compared to normal. Skin cancers BCC producemore MMP AP 1 and NF-KB, these inducedMMP 2 and MMP 9. The formation of collagen bundles is responsible for the strength, resiliency and elasticity of the skin. - In one embodiment of the invention single or multiple light sources may be used, to produce either a single dominant emissive wavelength, i.e., a narrowband multichromatic radiation, or multiple wavelengths (either monochromatic, narrowband multichromatic, wideband multichromatic, or combinations thereof). The single or multiple combinations may be applied either simultaneously or sequentially.
- For example a device emitting narrowband, multichromatic electromagnetic radiation with a dominant emissive wavelength of about 590 nm (+/− about 10 nm) and also some light in the 850 nm range and, optionally, a small amount in the 1060 nm range. It has been discovered that the combination of the visible 590 and the infrared 850 nm is bioactive. A special IR filter may also be added to reduce the IR component of the radiation that the target skin or tissue is exposed to, as this is believed to unsymmetrically dampen the shape of the IR/850 curve. Treatment examples of such a device are shown in the attached drawing figures and illustrate that at 850 nm, there is believed to be a ‘dose dependent’ effect on fibroblasts. Further, at a power level of about 1 mW/cm2, photomodulation occurs for anti aging phenotype effect (those skilled in the art will recognize that power meters cannot measure this precisely, so there may be some variation/error in meter methods). Generally, where a treatment that does not cause thermal injury is desired, an energy fluence of less than about 4 J/cm2 is preferable.
- The ratio of yellow light to IR radiation in the radiation used for treatment has been found to have an effect on the overall performance of the present system. Relative amounts of each type of radiation are believed to be important, more so than the actual radiation level (provided that ablation does not occur). At about 4 mW/cm2 for 590 nm and about 1 mW/cm2 for the 850 nm (i.e., a 4:1 ratio of yellow to IR) has been found to produce good results. Mother factor to consider is the shape of the amplitude vs. wavelength curve for the IR component of the system.
- The ‘code’ refers to the pulse scheme for various treatment regimen. This includes various factors such as pulse length, interpulse delay, and pulse repetition. For example a treatment may comprise a pulse code of 250 msec “on” time, 100 msec “off” time (or dark period), and 100 pulses. This produces a total energy fluence, in J/cm2, of 25 seconds times the power output level of the emitters. This permits a comparison of pulsed versus continuous wave treatment (the “code” for continuous wave treatment would be 1 pulse, an “on” time of whatever the treatment length is chosen to be, and an “off” time of 0 sec.) Examples showing various codes, ratios, and power levels and the resulting effect on the photoaging effect on certain genes, and other data, are shown in the attached data tables and drawing figures.
- The present invention is also related to a method and apparatus for treating sunburn and other sun-related photoeffects on human or mammalian skin. One approach is to use Retin A for prior to sun exposure and research is being conducted using vitamins C, E, and other antioxidants topically. Another approach being tried is the use of the antioxidant Lycopene, administered orally, to quench some of inflammation from sunburn. The present invention shows great improvement of such treatment methods, however.
- One may think of wrinkles, sun damage, and other sun-related photo effects as ‘solar scars’. They are cumulative injuries that result from repeated or long-term exposure to the sun. The human body employs and imperfect wound repair mechanism, thus the solar simulator of the present invention is, in some ways, a model for other wound healings. The present invention employs a treatment that simulates sunlight broken down into its component parts. The
UVA 1 portion is used in some embodiments, but there is UVB and combinations of UVA and UVR that are more oncogenic. For example, UV, and inparticular UVA 1, causes skin sagging and photoaging, changes to the dermal matrix and structural proteins, and upregulates MMPs. UV radiation also causes the upregulation of inflammatory pathways such as IL1, IL6 and NFkB. These pathways are known to affect aging and other sun-related skin disorders and environmental damage, such as smoking, pollution, drugs, diseases, thermal injuries, other wounds. - The present invention is believed to inhibit or reverse the effects of photoaging and other skin disorders by reversing the direction of gene up/down regulation from the unfavorable and destructive directions caused by the effects of the solar simulator UVA1 for things like collagen, MMP1, cJun which is important related to MMP1, IL/interleukins in inflammatory pathway, and cytochromes. The attached examples describe the use of the present system for illustrative treatments.
- The systems and methods of the present invention may be used in combination with various wound dressings like bandage strips modified to have a transparent covering, so that the desired spectra of photomodulation by LED or other light is transmitted to the wounded area of the skin or target tissue. One embodiment includes ‘trap door’ to permit the periodic inhibition of light transmission. The opening or translucent/transparent portion of the bandage may comprise an IR filter, as well. In instances where it is undesirable to include an opening as part of the bandage or wound dressing, the size of LED's and other light sources makes it possible to include a light source within the bandage. Such a source could be powered from a small battery and include means for having the light source automatically or manually apply treatment at regular intervals and according to a variety of preset codes (for example, a dressed chemical burn may require a different code than a cut or electrical burn). As well, various topical compositions for enhancing the penetration of the light through the skin or target tissue can be included in the dressing or bandage or applied to the skin or target tissue prior to covering the affected skin with the bandage or dressing.
- A light source within the bandage may also be coded to ‘release’ or to ‘activate’ substances or delivery vehicles for substances so that oxygen, antibacterial, antiviral, anti fungal, etc., or other agents released. Combinations of such compositions may be used as well.
- Another application would allow for the treatment of blood outside of the body (extracorporeally, in a phoresis device for example). The blood may be run through banks of arrays of LED, or other light or EMR, and then photomodulated either directly or by an agent that was photoactivatable, or both, to stimulate the immune system, treat disease, etc.
- The present system and method may also be used for retinal and other eye treatments, alone or along with antioxidant eyedrop-type medications, bioengineered peptides, and growth factors. Antioxidant eyedrops include, but are not limited to glutathione, vitamin C, vitamin E, catalase, ubiquinone, idebenone, etc.
- Other applications of the present invention include nerve regeneration, hormone manipulation (thyroid disease is common and is particularly contemplated due to the proximity of the thyroid to the skin). As well, photomodulating adipocytes for fat reduction, cellulite, etc. may be accomplished using light sources in the range of about 850-950 nm and 1000-1100 nm.
- The following examples illustrate embodiments of the invention, but should not be viewed as limiting the scope of the invention.
- Attached hereto are graphs, tables of data, and examples that further illustrate the various embodiments of the invention, as well as lists of gene products which can be regulated by methods of the invention. In the appendix, the results of two experiments which illustrate the invention are shown.
- Other embodiments and uses of the invention will be apparent to those skilled in the art from consideration of the specification and practice of the invention disclosed herein. All references cited herein, including all publications, U.S. and foreign patents and patent applications, are specifically and entirely incorporated by reference. It is intended that the specification and examples be considered exemplary only.
Claims (6)
1. (canceled)
2. A device, comprising:
more than one light source of narrowband, multi chromatic electromagnetic radiation,
wherein at least one light source emits radiation at a wavelength corresponding to yellow light and at least one light source emits radiation corresponding to infra-red light, and
wherein the device emits electromagnetic radiation at a fluence of less than 4 J/cm2.
3. The device of claim 2 , wherein at least one light source emits radiation having a dominant emissive wavelength of 580 nm to 600 nm and at least one light source emits radiation having a dominant emissive wavelength of 850 nm to 950 nm.
4. The device of claim 3 , wherein the at least one light source emits radiation having a dominant emissive wavelength of 590 nm at an energy output of 4 mW/cm2 and at least one light source emits radiation having a dominant emissive wavelength of 850 nm at an energy output of 1 mW/cm2.
5. The device of claim 2 , comprising at least one optical, mechanical, or electrical filter for varying the ratio of infra-red light intensity with respect to yellow light intensity.
6. The method of claim 2 , wherein the ratio of the intensity of yellow light to infra-red light is 4:1.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/807,653 US20150328479A1 (en) | 2003-07-31 | 2015-07-23 | System and method for the photodynamic treatment of burns, wounds, and related skin disorders |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49127703P | 2003-07-31 | 2003-07-31 | |
US10/903,483 US20050149150A1 (en) | 2003-07-31 | 2004-08-02 | System and method for the photodynamic treatment of burns, wounds, and related skin disorders |
US12/550,464 US9144690B2 (en) | 2003-07-31 | 2009-08-31 | System and method for the photodynamic treatment of burns, wounds, and related skin disorders |
US14/807,653 US20150328479A1 (en) | 2003-07-31 | 2015-07-23 | System and method for the photodynamic treatment of burns, wounds, and related skin disorders |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/550,464 Division US9144690B2 (en) | 2003-07-31 | 2009-08-31 | System and method for the photodynamic treatment of burns, wounds, and related skin disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
US20150328479A1 true US20150328479A1 (en) | 2015-11-19 |
Family
ID=34115488
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/903,483 Abandoned US20050149150A1 (en) | 2003-07-31 | 2004-08-02 | System and method for the photodynamic treatment of burns, wounds, and related skin disorders |
US12/550,464 Active 2025-01-07 US9144690B2 (en) | 2003-07-31 | 2009-08-31 | System and method for the photodynamic treatment of burns, wounds, and related skin disorders |
US14/807,653 Abandoned US20150328479A1 (en) | 2003-07-31 | 2015-07-23 | System and method for the photodynamic treatment of burns, wounds, and related skin disorders |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/903,483 Abandoned US20050149150A1 (en) | 2003-07-31 | 2004-08-02 | System and method for the photodynamic treatment of burns, wounds, and related skin disorders |
US12/550,464 Active 2025-01-07 US9144690B2 (en) | 2003-07-31 | 2009-08-31 | System and method for the photodynamic treatment of burns, wounds, and related skin disorders |
Country Status (9)
Country | Link |
---|---|
US (3) | US20050149150A1 (en) |
EP (1) | EP1648385B1 (en) |
JP (1) | JP4739202B2 (en) |
KR (1) | KR101160343B1 (en) |
CN (1) | CN101247768A (en) |
CA (1) | CA2533129A1 (en) |
ES (1) | ES2572976T3 (en) |
IL (1) | IL173123A0 (en) |
WO (1) | WO2005011606A2 (en) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999010046A1 (en) * | 1997-08-25 | 1999-03-04 | Advanced Photodynamic Technologies, Inc. | Treatment device for topical photodynamic therapy and method of making same |
US6887260B1 (en) | 1998-11-30 | 2005-05-03 | Light Bioscience, Llc | Method and apparatus for acne treatment |
US20060212025A1 (en) | 1998-11-30 | 2006-09-21 | Light Bioscience, Llc | Method and apparatus for acne treatment |
US9192780B2 (en) | 1998-11-30 | 2015-11-24 | L'oreal | Low intensity light therapy for treatment of retinal, macular, and visual pathway disorders |
US6283956B1 (en) | 1998-11-30 | 2001-09-04 | David H. McDaniels | Reduction, elimination, or stimulation of hair growth |
KR20060041161A (en) | 2003-04-10 | 2006-05-11 | 라이트 바이오사이언스, 엘엘씨 | Photomodulation methods and devices for regulating cell proliferation and gene expression |
US20050149150A1 (en) | 2003-07-31 | 2005-07-07 | Light Bioscience L.L.C. | System and method for the photodynamic treatment of burns, wounds, and related skin disorders |
US7686839B2 (en) * | 2005-01-26 | 2010-03-30 | Lumitex, Inc. | Phototherapy treatment devices for applying area lighting to a wound |
WO2006103678A2 (en) | 2005-03-31 | 2006-10-05 | Esther Mayer | Probe device, system and method for photobiomodulation of tissue lining a body cavity |
US20080269730A1 (en) * | 2005-04-14 | 2008-10-30 | Dotson Robert S | Ophthalmic Phototherapy Device and Associated Treatment Method |
US20070021807A1 (en) * | 2005-07-20 | 2007-01-25 | Eastman Kodak Company | Device for optically stimulating collagen formation in tissue |
CA2686929A1 (en) * | 2007-05-11 | 2008-11-20 | Clarimedix Inc. | Visible light modulation of mitochondrial function in hypoxia and disease |
JP2011500669A (en) * | 2007-10-17 | 2011-01-06 | ニュートゥリー カンパニー リミテッド | Novel uses of pandoratin derivatives or kaempferia pandurata extract containing the same |
FR2926985B1 (en) * | 2008-02-06 | 2010-05-21 | Oreal | ASSOCIATION OF LUMINOUS RADIATION AND A SUBSTRATE OF CYTOCHROME C OXIDASE TO IMPROVE THE APPEARANCE OF SKIN AND / OR HAIR |
US7834335B2 (en) * | 2008-10-27 | 2010-11-16 | Verilux, Inc. | Hand held sterilization devices |
US8105532B2 (en) * | 2008-10-27 | 2012-01-31 | Verilux, Inc. | Mobile disinfectant device and methods |
US20100121419A1 (en) * | 2008-11-13 | 2010-05-13 | Ryan Douglas | Control of light sources for light therapies |
CN101701183B (en) * | 2009-10-28 | 2012-07-18 | 福建师范大学 | Isolated cell photodynamic action effect reference apparatus based on LED array |
WO2011097358A1 (en) | 2010-02-05 | 2011-08-11 | Deland M Maitland | Led treatment of dermatologic toxicities associated with vascular endothelial growth factor inhibitors |
WO2011097354A1 (en) * | 2010-02-05 | 2011-08-11 | Deland M Maitland | Led treatment of dermatologic toxicities associated with multikinase inhibitors |
US20110196353A1 (en) * | 2010-02-05 | 2011-08-11 | Deland Maitland M | LED Treatment of Dermatologic Toxicities Associated with Epidermal Growth Factor Receptor Inhibitors |
US8496008B2 (en) | 2010-03-31 | 2013-07-30 | Oncologics, Inc. | Oral device for radiotherapy |
US8430102B2 (en) | 2010-03-31 | 2013-04-30 | Oncologics, Inc. | Oral device for radiotherapy |
KR101293882B1 (en) * | 2010-06-30 | 2013-08-06 | 단국대학교 산학협력단 | Composition for preventing and treating ischemic disease comprising lycopene |
EP2675524B1 (en) * | 2011-02-14 | 2017-05-10 | Merck Patent GmbH | Device and method for treatment of cells and cell tissue |
EP2500060B1 (en) * | 2011-03-17 | 2016-08-31 | JK-Holding GmbH | Device for irradiating actinic radiation of different wavelengths |
US8330121B2 (en) | 2011-05-03 | 2012-12-11 | Verilux, Inc. | Dynamic display and control of UV source for sanitization in mobile devices |
US9687669B2 (en) | 2011-11-09 | 2017-06-27 | John Stephan | Wearable light therapy apparatus |
CN103212162A (en) * | 2012-01-19 | 2013-07-24 | 福华电子股份有限公司 | Mixing photostimulation method and mixing photostimulation device |
FR2997019B1 (en) | 2012-10-23 | 2016-07-01 | Oreal | DEVICE, APPARATUS AND METHOD FOR COSMETIC TREATMENT WITH LIGHT |
FR2997018A1 (en) | 2012-10-23 | 2014-04-25 | Oreal | DEVICE AND METHOD FOR COSMETIC TREATMENT BY LIGHT |
SE538469C2 (en) * | 2013-10-07 | 2016-07-12 | Johansson Susanne | Device for controlling a laser probe |
WO2016040534A1 (en) | 2014-09-09 | 2016-03-17 | LumiThera, Inc. | Multi-wavelength phototherapy devices, systems, and methods for the non-invasive treatment of damaged or diseased tissue |
JP6598450B2 (en) * | 2014-10-28 | 2019-10-30 | 花王株式会社 | Gene detection method for skin property determination |
US10039600B2 (en) * | 2015-02-03 | 2018-08-07 | L'oreal | Apparatus and method for skin treatment using pulsed light |
US9687643B2 (en) * | 2015-02-03 | 2017-06-27 | L'oreal | Apparatus and method for skin treatment using continuous light |
KR101666838B1 (en) | 2015-05-13 | 2016-10-17 | 대구가톨릭대학교산학협력단 | Scar treatment Systems |
US20160346565A1 (en) * | 2015-05-29 | 2016-12-01 | Nathaniel L.R. Rhodes | Methods and apparatus to deliver therapeutic non-ultraviolet electromagnetic radiation to a body surface |
KR101762111B1 (en) * | 2015-07-06 | 2017-07-28 | 코스맥스 주식회사 | Cosmetic composition comprising Malva verticillata Seed extract for prevention of skin aging or anti-wrinkles |
WO2017019839A1 (en) | 2015-07-28 | 2017-02-02 | Photonmd, Llc | Phototherapy devices for treatment of dermatological disorders of the scalp |
US10525275B2 (en) | 2015-07-28 | 2020-01-07 | Photonmd, Inc. | Systems and methods for phototherapeutic modulation of nitric oxide |
US12109429B2 (en) | 2015-07-28 | 2024-10-08 | Know Bio, Llc | Phototherapeutic light for treatment of pathogens |
WO2018022775A1 (en) | 2016-07-27 | 2018-02-01 | Zhang Jack K | Componentry and devices for light therapy delivery and methods related thereto |
US20190083809A1 (en) | 2016-07-27 | 2019-03-21 | Z2020, Llc | Componentry and devices for light therapy delivery and methods related thereto |
CN108295382A (en) * | 2018-01-04 | 2018-07-20 | 华南农业大学 | Application of the He-Ne Lasers in skin wound treatment |
EP3803415A1 (en) * | 2018-06-04 | 2021-04-14 | Avon Products, Inc. | Protein biomarkers for identifying and treating aging skin and skin conditions |
FR3106058B1 (en) | 2020-01-09 | 2022-01-07 | Oreal | Cosmetic treatment process |
US11147984B2 (en) | 2020-03-19 | 2021-10-19 | Know Bio, Llc | Illumination devices for inducing biological effects |
US11986666B2 (en) | 2020-03-19 | 2024-05-21 | Know Bio, Llc | Illumination devices for inducing biological effects |
US12011611B2 (en) | 2020-03-19 | 2024-06-18 | Know Bio, Llc | Illumination devices for inducing biological effects |
US11975215B2 (en) | 2020-05-26 | 2024-05-07 | Know Bio, Llc | Devices and related methods for phototherapeutic treatment of skin |
US12115384B2 (en) | 2021-03-15 | 2024-10-15 | Know Bio, Llc | Devices and methods for illuminating tissue to induce biological effects |
US11654294B2 (en) | 2021-03-15 | 2023-05-23 | Know Bio, Llc | Intranasal illumination devices |
US12089716B2 (en) | 2022-04-29 | 2024-09-17 | L'oreal | Applicator with cartridges configured to deliver vibration for skin treatment |
CN118001374A (en) * | 2023-02-13 | 2024-05-10 | 上海萨美细胞技术有限公司 | Medicine for resisting skin fibrosis |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5312395A (en) * | 1990-03-14 | 1994-05-17 | Boston University | Method of treating pigmented lesions using pulsed irradiation |
US5586981A (en) * | 1994-08-25 | 1996-12-24 | Xin-Hua Hu | Treatment of cutaneous vascular and pigmented lesions |
US6162212A (en) * | 1999-04-19 | 2000-12-19 | Esc Medical Systems, Ltd. | Optimal procedure for performing a hair removal |
US6235015B1 (en) * | 1997-05-14 | 2001-05-22 | Applied Optronics Corporation | Method and apparatus for selective hair depilation using a scanned beam of light at 600 to 1000 nm |
US6283956B1 (en) * | 1998-11-30 | 2001-09-04 | David H. McDaniels | Reduction, elimination, or stimulation of hair growth |
US20020045891A1 (en) * | 1996-08-29 | 2002-04-18 | Clement Robert Marc | Wrinkle reduction |
US20020095143A1 (en) * | 2000-12-18 | 2002-07-18 | Key Douglas J. | Method of amplifying a beneficial selective skin response to light energy |
US20030004499A1 (en) * | 2000-01-13 | 2003-01-02 | Mcdaniel David H. | Method and apparatus for the photomodulation of living cells |
US6537302B1 (en) * | 1999-01-20 | 2003-03-25 | Biolight Patent Holding Ab | Means for external medical treatment by means of light |
US6663658B1 (en) * | 1999-04-27 | 2003-12-16 | The General Hospital Corporation | Phototherapy method for treatment of acne |
US20040147985A1 (en) * | 2003-01-27 | 2004-07-29 | Altus Medical, Inc. | Dermatological treatment flashlamp device and method |
US6881212B1 (en) * | 1999-03-05 | 2005-04-19 | Icn Photonics Limited | Skin wrinkle reduction using pulsed light |
Family Cites Families (377)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3499437A (en) * | 1967-03-10 | 1970-03-10 | Ultrasonic Systems | Method and apparatus for treatment of organic structures and systems thereof with ultrasonic energy |
US3876907A (en) * | 1970-12-10 | 1975-04-08 | Controlled Environment Syst | Plant growth system |
US3930335A (en) * | 1973-04-02 | 1976-01-06 | Controlled Environment Systems, Inc. | Plant growth system |
US4309989A (en) * | 1976-02-09 | 1982-01-12 | The Curators Of The University Of Missouri | Topical application of medication by ultrasound with coupling agent |
US4069823A (en) * | 1976-04-19 | 1978-01-24 | Viktor Leonidovich Isakov | Apparatus for laser therapy |
US4458678A (en) * | 1981-10-26 | 1984-07-10 | Massachusetts Institute Of Technology | Cell-seeding procedures involving fibrous lattices |
DE3151494A1 (en) * | 1981-12-24 | 1983-07-21 | Mutzhas Maximilian F | METHOD FOR PHOTOTHERAPY OF DERMATOSES, ESPECIALLY PSORIASIS |
SE8200913L (en) * | 1982-02-16 | 1983-08-17 | Integrerad Teknik Igt Hb | DEVICE FOR LEDS |
US4649151A (en) * | 1982-09-27 | 1987-03-10 | Health Research, Inc. | Drugs comprising porphyrins |
DE3306981C2 (en) * | 1983-02-28 | 1987-11-12 | Wolfram 8048 Haimhausen Weinberg | Device for the photocoagulation of biological tissue |
GB2157176A (en) | 1984-04-09 | 1985-10-23 | Lasercare | Promoting hair growth by laser |
US4646743A (en) * | 1984-05-09 | 1987-03-03 | Parris Danny M | Therapy radiation apparatus for veterinary medicine |
US4621287A (en) * | 1984-05-29 | 1986-11-04 | Rca Corporation | Time-multiplexing of an interleaved spectrum of a television signal |
US4629363A (en) * | 1984-11-02 | 1986-12-16 | Rose Timothy M | Continuous conduit laying apparatus |
US4603496A (en) * | 1985-02-04 | 1986-08-05 | Adaptive Micro Systems, Inc. | Electronic display with lens matrix |
US4753958A (en) * | 1985-02-07 | 1988-06-28 | University Of Cal | Photochemotherapy of epithelial diseases with derivatives of hematoporphyrins |
DE3603156A1 (en) * | 1986-02-03 | 1987-08-06 | Zeiss Carl Fa | DEVICE FOR THERAPEUTIC RADIATION OF ORGANIC TISSUE WITH LASER RADIATION |
US5460939A (en) * | 1986-04-18 | 1995-10-24 | Advanced Tissue Sciences, Inc. | Temporary living skin replacement |
US5266480A (en) * | 1986-04-18 | 1993-11-30 | Advanced Tissue Sciences, Inc. | Three-dimensional skin culture system |
JPS633873A (en) * | 1986-06-23 | 1988-01-08 | 富士電機株式会社 | Laser remedy device |
US4767402A (en) * | 1986-07-08 | 1988-08-30 | Massachusetts Institute Of Technology | Ultrasound enhancement of transdermal drug delivery |
JPS63111886A (en) * | 1986-10-29 | 1988-05-17 | 呉羽化学工業株式会社 | Cancer remedy apparatus using optical diode |
US5283255A (en) * | 1987-01-20 | 1994-02-01 | The University Of British Columbia | Wavelength-specific cytotoxic agents |
EP0298661B1 (en) | 1987-07-08 | 1994-06-15 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Novel vibrator system and vibrotherapeutic device using the same |
US4764379A (en) * | 1987-08-24 | 1988-08-16 | Alza Corporation | Transdermal drug delivery device with dual permeation enhancers |
US5001556A (en) * | 1987-09-30 | 1991-03-19 | Olympus Optical Co., Ltd. | Endoscope apparatus for processing a picture image of an object based on a selected wavelength range |
US5259380A (en) * | 1987-11-04 | 1993-11-09 | Amcor Electronics, Ltd. | Light therapy system |
US4837027A (en) * | 1987-11-09 | 1989-06-06 | Alza Corporation | Transdermal drug delivery device |
US4781924A (en) * | 1987-11-09 | 1988-11-01 | Alza Corporation | Transdermal drug delivery device |
US4930504A (en) * | 1987-11-13 | 1990-06-05 | Diamantopoulos Costas A | Device for biostimulation of tissue and method for treatment of tissue |
JPH07100219B2 (en) | 1987-11-25 | 1995-11-01 | 石川島播磨重工業株式会社 | Thin plate manufacturing equipment |
IT212331Z2 (en) * | 1987-11-27 | 1989-07-04 | Lorenzo Molinari | EQUIPMENT FOR ADJUSTABLE REMOVAL OF SURFACE PORTIONS OF HUMAN FABRIC |
US4888354A (en) * | 1987-12-21 | 1989-12-19 | Theratech, Inc. | Skin penetration enhancement using free base and acid addition salt combinations of active agents |
US4935665A (en) * | 1987-12-24 | 1990-06-19 | Mitsubishi Cable Industries Ltd. | Light emitting diode lamp |
US4969912A (en) * | 1988-02-18 | 1990-11-13 | Kelman Charles D | Human collagen processing and autoimplant use |
US4907132A (en) * | 1988-03-22 | 1990-03-06 | Lumitex, Inc. | Light emitting panel assemblies and method of making same |
US5198460A (en) | 1988-07-20 | 1993-03-30 | Health Research Inc. | Pyropheophorbides and their use in photodynamic therapy |
US5147349A (en) * | 1988-10-07 | 1992-09-15 | Spectra-Physics, Inc. | Diode laser device for photocoagulation of the retina |
US5012609A (en) * | 1988-12-12 | 1991-05-07 | Automated Agriculture Associates, Inc. | Method and apparatus for irradiation of plants using optoelectronic devices |
US5021452A (en) * | 1989-01-09 | 1991-06-04 | The Board Of Regents Of The University Of Washington | Process for enhancing wound healing |
US6099522A (en) | 1989-02-06 | 2000-08-08 | Visx Inc. | Automated laser workstation for high precision surgical and industrial interventions |
US5034613A (en) * | 1989-11-14 | 1991-07-23 | Cornell Research Foundation, Inc. | Two-photon laser microscopy |
US5257173A (en) * | 1989-12-13 | 1993-10-26 | Stanley Electric Co., Ltd. | Light irradiating apparatus having light emitting diode used as light source |
JPH0716304Y2 (en) | 1990-01-19 | 1995-04-12 | 富士通株式会社 | Memory circuit protection structure |
US5016615A (en) * | 1990-02-20 | 1991-05-21 | Riverside Research Institute | Local application of medication with ultrasound |
US5231975A (en) * | 1990-02-23 | 1993-08-03 | Cygnus Therapeutic Systems | Ultrasound-enhanced delivery of materials into and through the skin |
US5115805A (en) * | 1990-02-23 | 1992-05-26 | Cygnus Therapeutic Systems | Ultrasound-enhanced delivery of materials into and through the skin |
US5071416A (en) * | 1990-05-02 | 1991-12-10 | Metalaser Technologies, Inc. | Method of and apparatus for laser-assisted therapy |
US5549660A (en) * | 1990-11-15 | 1996-08-27 | Amron, Ltd. | Method of treating acne |
US5500009A (en) * | 1990-11-15 | 1996-03-19 | Amron, Ltd. | Method of treating herpes |
US6723698B2 (en) | 1991-03-11 | 2004-04-20 | Curis, Inc. | Methods and compositions for the treatment of motor neuron injury and neuropathy |
CA2083165C (en) * | 1991-03-29 | 1996-07-09 | Ann Brannan | Device and method for treating facial lines |
US5198465A (en) * | 1991-06-19 | 1993-03-30 | Dioguardi Francesco S | Compositions based on amino acids for preventing and treating precursor deficiencies in the synthesis of collagen |
US5262401A (en) * | 1991-06-28 | 1993-11-16 | Cytopharm, Inc. | Porphycene compounds for photodynamic therapy |
US5445146A (en) * | 1995-03-31 | 1995-08-29 | Bellinger; Gary J. | Biological tissue stimulation by low level optical energy |
US5951596A (en) | 1991-07-01 | 1999-09-14 | Laser Biotherapy Inc | Biological tissue stimulation by optical energy |
US5171215A (en) * | 1991-08-22 | 1992-12-15 | Flanagan Dennis F | Endermic method and apparatus |
US5370642A (en) * | 1991-09-25 | 1994-12-06 | Keller; Gregory S. | Method of laser cosmetic surgery |
US5752948A (en) | 1991-10-29 | 1998-05-19 | Thermolase Corporation | Hair removal method |
US5226907A (en) * | 1991-10-29 | 1993-07-13 | Tankovich Nikolai I | Hair removal device and method |
US5817089A (en) * | 1991-10-29 | 1998-10-06 | Thermolase Corporation | Skin treatment process using laser |
US5752949A (en) * | 1991-10-29 | 1998-05-19 | Thermolase Corporation | Hair removal method |
US5871480A (en) | 1991-10-29 | 1999-02-16 | Thermolase Corporation | Hair removal using photosensitizer and laser |
US5423803A (en) * | 1991-10-29 | 1995-06-13 | Thermotrex Corporation | Skin surface peeling process using laser |
US5425728A (en) * | 1991-10-29 | 1995-06-20 | Tankovich; Nicolai I. | Hair removal device and method |
US5279538A (en) | 1991-11-18 | 1994-01-18 | E. I. Du Pont De Nemours And Company | Centrifuge rotor having a predetermined region of failure |
CH685148A5 (en) | 1991-11-20 | 1995-04-13 | Erik Larsen | Apparatus for the photodynamic stimulation of cells. |
GB2262043B (en) | 1991-12-02 | 1995-08-16 | John A Orpin | Pulsed energy stimulator device |
IL100545A (en) * | 1991-12-29 | 1995-03-15 | Dimotech Ltd | Apparatus for photodynamic therapy treatment |
US5756117A (en) | 1992-04-08 | 1998-05-26 | International Medical Asscociates, Inc. | Multidose transdermal drug delivery system |
US5405368A (en) | 1992-10-20 | 1995-04-11 | Esc Inc. | Method and apparatus for therapeutic electromagnetic treatment |
US5755752A (en) * | 1992-04-24 | 1998-05-26 | Segal; Kim Robin | Diode laser irradiation system for biological tissue stimulation |
WO1993021842A1 (en) | 1992-04-30 | 1993-11-11 | Quadra Logic Technologies, Inc. | High-power light-emitting diodes for photodynamic therapy |
DE4223004A1 (en) * | 1992-07-13 | 1994-01-20 | Liedtke Pharmed Gmbh | Single-dose semi-solid topical dosage form for transdermal therapy |
US5278432A (en) * | 1992-08-27 | 1994-01-11 | Quantam Devices, Inc. | Apparatus for providing radiant energy |
US5492135A (en) * | 1992-09-09 | 1996-02-20 | Devore; Dale P. | Collagen modulators for use in photoablation excimer laser keratectomy |
US5421816A (en) * | 1992-10-14 | 1995-06-06 | Endodermic Medical Technologies Company | Ultrasonic transdermal drug delivery system |
US5620478A (en) * | 1992-10-20 | 1997-04-15 | Esc Medical Systems Ltd. | Method and apparatus for therapeutic electromagnetic treatment |
US5683380A (en) * | 1995-03-29 | 1997-11-04 | Esc Medical Systems Ltd. | Method and apparatus for depilation using pulsed electromagnetic radiation |
GB2272278B (en) * | 1992-10-23 | 1997-04-09 | Cancer Res Campaign Tech | Light source |
US5360824A (en) * | 1993-02-05 | 1994-11-01 | Barker Donald E | Human skin cleansing and wrinkle-reducing cream |
US5445608A (en) * | 1993-08-16 | 1995-08-29 | James C. Chen | Method and apparatus for providing light-activated therapy |
US5397352A (en) * | 1993-08-27 | 1995-03-14 | Burres; Steven | Method of recollagenation |
US5420768A (en) * | 1993-09-13 | 1995-05-30 | Kennedy; John | Portable led photocuring device |
US5647866A (en) * | 1993-11-09 | 1997-07-15 | Zaias; Nardo | Method of hair depilation |
US5814599A (en) * | 1995-08-04 | 1998-09-29 | Massachusetts Insitiute Of Technology | Transdermal delivery of encapsulated drugs |
US5445611A (en) * | 1993-12-08 | 1995-08-29 | Non-Invasive Monitoring Company (Nimco) | Enhancement of transdermal delivery with ultrasound and chemical enhancers |
SE504298C2 (en) | 1994-01-20 | 1996-12-23 | Biolight Patent Holding Ab | Device for wound healing by light |
SE502784C2 (en) * | 1994-01-20 | 1996-01-15 | Biolight Patent Holding Ab | Device for medical treatment is externalized by light |
US5358503A (en) * | 1994-01-25 | 1994-10-25 | Bertwell Dale E | Photo-thermal therapeutic device and method |
IL108918A (en) * | 1994-03-10 | 1997-04-15 | Medic Lightech Ltd | Apparatus for efficient photodynamic treatment |
US5616140A (en) * | 1994-03-21 | 1997-04-01 | Prescott; Marvin | Method and apparatus for therapeutic laser treatment |
US5474528A (en) * | 1994-03-21 | 1995-12-12 | Dusa Pharmaceuticals, Inc. | Combination controller and patch for the photodynamic therapy of dermal lesion |
US5698866A (en) * | 1994-09-19 | 1997-12-16 | Pdt Systems, Inc. | Uniform illuminator for phototherapy |
US5669916A (en) * | 1994-09-28 | 1997-09-23 | The General Hospital Corporation | Method of hair removal |
WO1996011723A1 (en) | 1994-10-17 | 1996-04-25 | Australasian Medical Technology Limited | Devices and methods for implementation of pulsed electromagnetic field therapy |
US5660461A (en) * | 1994-12-08 | 1997-08-26 | Quantum Devices, Inc. | Arrays of optoelectronic devices and method of making same |
US5643334A (en) * | 1995-02-07 | 1997-07-01 | Esc Medical Systems Ltd. | Method and apparatus for the diagnostic and composite pulsed heating and photodynamic therapy treatment |
US5728090A (en) | 1995-02-09 | 1998-03-17 | Quantum Devices, Inc. | Apparatus for irradiating living cells |
JP3670064B2 (en) * | 1995-03-15 | 2005-07-13 | 啓介 小林 | Biological light irradiation device and its lamp |
US5660836A (en) * | 1995-05-05 | 1997-08-26 | Knowlton; Edward W. | Method and apparatus for controlled contraction of collagen tissue |
US5658323A (en) * | 1995-07-12 | 1997-08-19 | Miller; Iain D. | Method and apparatus for dermatology treatment |
US5947921A (en) | 1995-12-18 | 1999-09-07 | Massachusetts Institute Of Technology | Chemical and physical enhancers and ultrasound for transdermal drug delivery |
US6008211A (en) * | 1995-07-27 | 1999-12-28 | Pdt Pharmaceuticals, Inc. | Photoactivatable compounds comprising benzochlorin and furocoumarin |
US5591444A (en) * | 1995-07-28 | 1997-01-07 | Isolagen Technologies, Inc. | Use of autologous dermal fibroblasts for the repair of skin and soft tissue defects |
US20070208328A1 (en) | 1995-08-31 | 2007-09-06 | Dmitri Boutoussov | Contra-angel rotating handpiece having tactile-feedback tip ferrule |
US5849029A (en) | 1995-12-26 | 1998-12-15 | Esc Medical Systems, Ltd. | Method for controlling the thermal profile of the skin |
US5964749A (en) | 1995-09-15 | 1999-10-12 | Esc Medical Systems Ltd. | Method and apparatus for skin rejuvenation and wrinkle smoothing |
US5836999A (en) * | 1995-09-28 | 1998-11-17 | Esc Medical Systems Ltd. | Method and apparatus for treating psoriasis using pulsed electromagnetic radiation |
US5618275A (en) * | 1995-10-27 | 1997-04-08 | Sonex International Corporation | Ultrasonic method and apparatus for cosmetic and dermatological applications |
US5837224A (en) * | 1996-01-19 | 1998-11-17 | The Regents Of The University Of Michigan | Method of inhibiting photoaging of skin |
US6143287A (en) | 1996-02-27 | 2000-11-07 | New York Blood Center, Inc. | Method and composition for hair removal |
US5800478A (en) * | 1996-03-07 | 1998-09-01 | Light Sciences Limited Partnership | Flexible microcircuits for internal light therapy |
US5843072A (en) | 1996-11-07 | 1998-12-01 | Cynosure, Inc. | Method for treatment of unwanted veins and device therefor |
EP0906770A1 (en) | 1996-04-11 | 1999-04-07 | Nikolai Taimourasovich Bagraev | Method for treating pathological conditions of tissues with non-coherent radiation and device therefor |
US5766214A (en) * | 1996-04-18 | 1998-06-16 | Mehl, Sr.; Thomas L. | Melanin enhanced photothermolysis hair removal |
EP0840617B1 (en) | 1996-04-26 | 2008-06-18 | University Of Ottawa | Use of naip or iap for the treatment and prevention of neuronal disease |
US5662644A (en) * | 1996-05-14 | 1997-09-02 | Mdlt, Inc. | Dermatological laser apparatus and method |
SE509718C2 (en) | 1996-06-07 | 1999-03-01 | Biolight Patent Holding Ab | Device for medical external light therapy |
SE509003C2 (en) | 1996-06-07 | 1998-11-23 | Biolight Patent Holding Ab | Device for medical external treatment by monochromatic light |
US5913883A (en) | 1996-08-06 | 1999-06-22 | Alexander; Dane | Therapeutic facial mask |
US6214034B1 (en) | 1996-09-04 | 2001-04-10 | Radiancy, Inc. | Method of selective photothermolysis |
CN1202668C (en) | 1996-09-11 | 2005-05-18 | 松下电器产业株式会社 | Program reception lexecution apparatus which can start execution of program even when only part of program is received, and program transmitter for it |
US5665053A (en) * | 1996-09-27 | 1997-09-09 | Jacobs; Robert A. | Apparatus for performing endermology with ultrasound |
AU713059B2 (en) | 1996-10-01 | 1999-11-25 | Hamamatsu Photonics K.K. | Iminochlorin aspartic acid derivatives |
US6024717A (en) | 1996-10-24 | 2000-02-15 | Vibrx, Inc. | Apparatus and method for sonically enhanced drug delivery |
US7036516B1 (en) | 1996-10-30 | 2006-05-02 | Xantech Pharmaceuticals, Inc. | Treatment of pigmented tissues using optical energy |
US5829448A (en) * | 1996-10-30 | 1998-11-03 | Photogen, Inc. | Method for improved selectivity in photo-activation of molecular agents |
GB9623627D0 (en) | 1996-11-13 | 1997-01-08 | Meditech International Inc | Method and apparatus for photon therapy |
US20060149343A1 (en) | 1996-12-02 | 2006-07-06 | Palomar Medical Technologies, Inc. | Cooling system for a photocosmetic device |
US20080294152A1 (en) | 1996-12-02 | 2008-11-27 | Palomar Medical Technologies, Inc. | Cooling System For A Photocosmetic Device |
US8182473B2 (en) | 1999-01-08 | 2012-05-22 | Palomar Medical Technologies | Cooling system for a photocosmetic device |
US7204832B2 (en) | 1996-12-02 | 2007-04-17 | Pálomar Medical Technologies, Inc. | Cooling system for a photo cosmetic device |
US6162211A (en) | 1996-12-05 | 2000-12-19 | Thermolase Corporation | Skin enhancement using laser light |
US6190376B1 (en) | 1996-12-10 | 2001-02-20 | Asah Medico A/S | Apparatus for tissue treatment |
US6063108A (en) * | 1997-01-06 | 2000-05-16 | Salansky; Norman | Method and apparatus for localized low energy photon therapy (LEPT) |
US5997569A (en) | 1997-01-29 | 1999-12-07 | Light Sciences Limited Partnership | Flexible and adjustable grid for medical therapy |
US5810801A (en) | 1997-02-05 | 1998-09-22 | Candela Corporation | Method and apparatus for treating wrinkles in skin using radiation |
US5904659A (en) | 1997-02-14 | 1999-05-18 | Exogen, Inc. | Ultrasonic treatment for wounds |
EP1005333B1 (en) * | 1997-02-25 | 2005-01-12 | The Regents Of The University Of Michigan | Methods and compositions for preventing and treating chronological aging in human skin |
US5957960A (en) | 1997-05-05 | 1999-09-28 | Light Sciences Limited Partnership | Internal two photon excitation device for delivery of PDT to diffuse abnormal cells |
DE69825447T2 (en) | 1997-05-15 | 2005-09-15 | Palomar Medical Technologies, Inc., Burlington | DEVICE FOR DERMATOLOGICAL TREATMENT |
US6312450B1 (en) | 1997-05-20 | 2001-11-06 | Natural Vision Center, Inc. | System and method for improving the appearance of skin |
TWI234467B (en) * | 1997-06-04 | 2005-06-21 | Univ Michigan | Composition for inhibiting photoaging of skin |
US5968034A (en) | 1997-06-24 | 1999-10-19 | Laser Aesthetics, Inc. | Pulsed filament lamp for dermatological treatment |
US5954675A (en) | 1997-07-07 | 1999-09-21 | Dellagatta; Enrico Michael | Method of ultrasonic therapy |
AU750933B2 (en) | 1997-07-28 | 2002-08-01 | Dermatolazer Technologies Ltd. | Phototherapy based method for treating pathogens and composition for effecting same |
US6251127B1 (en) | 1997-08-25 | 2001-06-26 | Advanced Photodynamic Technologies, Inc. | Dye treatment solution and photodynamic therapy and method of using same |
US6074382A (en) | 1997-08-29 | 2000-06-13 | Asah Medico A/S | Apparatus for tissue treatment |
EP1719541A1 (en) | 1997-10-08 | 2006-11-08 | The General Hospital Corporation | Phototherapy systems |
GB9721506D0 (en) | 1997-10-10 | 1997-12-10 | Virulite Limited | Treatment of diseases |
IL122016A (en) | 1997-10-22 | 2001-09-13 | Tav Tech Ltd | Apparatus for dermal abrasion |
US6113559A (en) | 1997-12-29 | 2000-09-05 | Klopotek; Peter J. | Method and apparatus for therapeutic treatment of skin with ultrasound |
AU740999B2 (en) | 1998-01-08 | 2001-11-22 | Sontra Medical, Inc. | Sonophoretic enhanced transdermal transport |
DE69900748T2 (en) | 1998-01-27 | 2002-09-26 | Povl Kaas | DEVICE FOR INTENSITY MEASUREMENT OF THE UV LIGHT OF A LAMP AND SYSTEM FOR UV TREATMENT WITH SUCH A DEVICE |
US20020055702A1 (en) | 1998-02-10 | 2002-05-09 | Anthony Atala | Ultrasound-mediated drug delivery |
EP1566149A1 (en) | 1998-03-12 | 2005-08-24 | Palomar Medical Technologies, Inc. | System for electromagnetic radiation of the skin |
US6398753B2 (en) * | 1998-04-03 | 2002-06-04 | Mcdaniel David H. | Ultrasound enhancement of percutaneous drug absorption |
US6030374A (en) * | 1998-05-29 | 2000-02-29 | Mcdaniel; David H. | Ultrasound enhancement of percutaneous drug absorption |
RU2145247C1 (en) * | 1998-04-10 | 2000-02-10 | Жаров Владимир Павлович | Photomatrix therapeutic device for treatment of extended pathologies |
US6223071B1 (en) | 1998-05-01 | 2001-04-24 | Dusa Pharmaceuticals Inc. | Illuminator for photodynamic therapy and diagnosis which produces substantially uniform intensity visible light |
US7004933B2 (en) | 1998-05-29 | 2006-02-28 | Light Bioscience L.L.C. | Ultrasound enhancement of percutaneous drug absorption |
US6110106A (en) | 1998-06-24 | 2000-08-29 | Biomax Technologies, Inc. | Endoscopes and methods relating to direct viewing of a target tissue |
AU4645099A (en) | 1998-07-09 | 2000-02-01 | Yoram Harth | Apparatus and method for efficient high energy photodynamic therapy of acne vulgaris and seborrhea |
WO2000002620A1 (en) | 1998-07-13 | 2000-01-20 | Genetronics, Inc. | Method and apparatus for electrically assisted topical delivery of agents for cosmetic applications |
EP1096897A1 (en) | 1998-07-13 | 2001-05-09 | Nobel Biocare AB | Universal impression coping system |
US6048301A (en) | 1998-07-13 | 2000-04-11 | Sabuda; Thomas J. | Method and device for stimulating biological processes |
US6096066A (en) | 1998-09-11 | 2000-08-01 | Light Sciences Limited Partnership | Conformal patch for administering light therapy to subcutaneous tumors |
JP2000202044A (en) * | 1998-11-10 | 2000-07-25 | Ya Man Ltd | Laser hair grower |
US6887260B1 (en) | 1998-11-30 | 2005-05-03 | Light Bioscience, Llc | Method and apparatus for acne treatment |
US6676655B2 (en) | 1998-11-30 | 2004-01-13 | Light Bioscience L.L.C. | Low intensity light therapy for the manipulation of fibroblast, and fibroblast-derived mammalian cells and collagen |
US9192780B2 (en) | 1998-11-30 | 2015-11-24 | L'oreal | Low intensity light therapy for treatment of retinal, macular, and visual pathway disorders |
US6936044B2 (en) | 1998-11-30 | 2005-08-30 | Light Bioscience, Llc | Method and apparatus for the stimulation of hair growth |
US20060212025A1 (en) | 1998-11-30 | 2006-09-21 | Light Bioscience, Llc | Method and apparatus for acne treatment |
US6402739B1 (en) | 1998-12-08 | 2002-06-11 | Y-Beam Technologies, Inc. | Energy application with cooling |
US6183773B1 (en) | 1999-01-04 | 2001-02-06 | The General Hospital Corporation | Targeting of sebaceous follicles as a treatment of sebaceous gland disorders |
SE522249C2 (en) * | 1999-01-13 | 2004-01-27 | Biolight Patent Holding Ab | Control device for controlling external processing by light |
US6231528B1 (en) | 1999-01-15 | 2001-05-15 | Jonathan J. Kaufman | Ultrasonic and growth factor bone-therapy: apparatus and method |
CA2356532A1 (en) | 1999-01-15 | 2000-07-20 | Light Sciences Corporation | Noninvasive vascular therapy |
US6187029B1 (en) | 1999-03-02 | 2001-02-13 | Physician's Technology, Llc | Photo-thermal treatment device |
US7041094B2 (en) | 1999-03-15 | 2006-05-09 | Cutera, Inc. | Tissue treatment device and method |
US6267779B1 (en) * | 1999-03-29 | 2001-07-31 | Medelaser, Llc | Method and apparatus for therapeutic laser treatment |
GB9912877D0 (en) | 1999-06-04 | 1999-08-04 | Sls Biophile Limited | Tissue rejuvenation |
US20040122492A1 (en) | 1999-07-07 | 2004-06-24 | Yoram Harth | Phototherapeutic treatment of skin conditions |
US20020173833A1 (en) | 1999-07-07 | 2002-11-21 | Avner Korman | Apparatus and method for high energy photodynamic therapy of acne vulgaris, seborrhea and other skin disorders |
US6290713B1 (en) | 1999-08-24 | 2001-09-18 | Thomas A. Russell | Flexible illuminators for phototherapy |
IL133253A0 (en) | 1999-12-01 | 2001-04-30 | Yeda Res & Dev | Chlorophyll and bacteriochlorophyll esters, their preparation and pharmaceutical compositions comprising them |
US20030036749A1 (en) | 1999-12-10 | 2003-02-20 | Durkin Anthony J. | Method of treating disorders associated with sebaceous follicles |
JP2001268812A (en) | 2000-03-23 | 2001-09-28 | Sanyo Electric Co Ltd | Portable electric equipment with built-in battery |
GB2360459B (en) * | 2000-03-23 | 2002-08-07 | Photo Therapeutics Ltd | Therapeutic light source and method |
US6719749B1 (en) | 2000-06-01 | 2004-04-13 | Medical Components, Inc. | Multilumen catheter assembly and methods for making and inserting the same |
EP1289440B1 (en) | 2000-06-01 | 2010-01-20 | The General Hospital Corporation | Selective photocoagulation |
CA2413660A1 (en) * | 2000-07-06 | 2002-01-17 | The Regents Of The University Of Michigan | Uva (>360-400) and uvb (300-325) specific sunscreens |
US6471716B1 (en) | 2000-07-11 | 2002-10-29 | Joseph P. Pecukonis | Low level light therapy method and apparatus with improved wavelength, temperature and voltage control |
US6413268B1 (en) | 2000-08-11 | 2002-07-02 | Raymond A. Hartman | Apparatus and method for targeted UV phototherapy of skin disorders |
AU2000267381A1 (en) | 2000-08-28 | 2002-03-13 | Korea Research Institute Of Chemical Technology | Resins having vinyl ether linker for the solid phase organic synthesis |
US6602275B1 (en) * | 2000-09-18 | 2003-08-05 | Jana Sullivan | Device and method for therapeutic treatment of living organisms |
US6524330B1 (en) | 2000-10-27 | 2003-02-25 | Bahram Khoobehi | Method of ocular treatment |
US6529543B1 (en) | 2000-11-21 | 2003-03-04 | The General Hospital Corporation | Apparatus for controlling laser penetration depth |
AU2002245119A1 (en) | 2000-12-15 | 2002-07-30 | Sloan-Kettering Institute For Cancer Research | Beam-steering of multi-chromatic light using acousto-optical deflectors and dispersion-compensatory optics |
EP2311399A3 (en) | 2000-12-28 | 2011-08-10 | Palomar Medical Technologies, Inc. | Method and apparatus for therapeutic EMR treatment of the skin |
US9561386B2 (en) | 2001-03-06 | 2017-02-07 | Lexington International, Llc | Apparatus and method for stimulating hair growth |
US6497719B2 (en) | 2001-03-06 | 2002-12-24 | Henry Pearl | Apparatus and method for stimulating hair growth |
DE10123926A1 (en) | 2001-03-08 | 2002-09-19 | Optomed Optomedical Systems Gmbh | irradiation device |
GB0113121D0 (en) | 2001-05-30 | 2001-07-18 | Univ Leeds | Biologically active photosensitisers |
AU2002316384A1 (en) * | 2001-06-26 | 2003-03-03 | Photomed Technologies, Inc. | Multiple wavelength illuminator |
BR0117084A (en) | 2001-06-27 | 2004-08-03 | Radiancy Inc | Apparatus for improving acne symptoms of a skin region |
US6835306B2 (en) * | 2001-07-06 | 2004-12-28 | Spx Corporation | Return-side filter for use in a vehicle transmission |
US20030009158A1 (en) | 2001-07-09 | 2003-01-09 | Perricone Nicholas V. | Skin treatments using blue and violet light |
US7195755B2 (en) | 2001-08-20 | 2007-03-27 | L'oreal S.A. | Compositions comprising at least one hydroxide compound and at least one reducing agent, and methods for relaxing hair |
KR20040048888A (en) | 2001-08-22 | 2004-06-10 | 라이트 바이오사이언스 인코포레이티드 | Method and apparatus for acne treatment |
US7264629B2 (en) | 2001-11-09 | 2007-09-04 | Qlt, Inc. | Photodynamic therapy for the treatment of hair loss |
US6960201B2 (en) | 2002-02-11 | 2005-11-01 | Quanticum, Llc | Method for the prevention and treatment of skin and nail infections |
US7081128B2 (en) | 2002-03-04 | 2006-07-25 | Hart Barry M | Phototherapy device and method of use |
US20070038206A1 (en) | 2004-12-09 | 2007-02-15 | Palomar Medical Technologies, Inc. | Photocosmetic device |
US6664217B1 (en) | 2002-07-18 | 2003-12-16 | Unilever Home & Personal Care, Usa Division Of Conopco, Inc. | Toilet bar having simultaneous exfoliating and moisturizing properties |
US20070219604A1 (en) | 2006-03-20 | 2007-09-20 | Palomar Medical Technologies, Inc. | Treatment of tissue with radiant energy |
US7131990B2 (en) | 2002-10-07 | 2006-11-07 | Natus Medical Inc. | Phototherapy system and device |
KR20050062597A (en) | 2002-10-07 | 2005-06-23 | 팔로마 메디칼 테크놀로지스, 인코포레이티드 | Apparatus for performing photobiostimulation |
US6866678B2 (en) | 2002-12-10 | 2005-03-15 | Interbational Technology Center | Phototherapeutic treatment methods and apparatus |
US7267673B2 (en) | 2002-12-12 | 2007-09-11 | Pacific Biosciences Laboratories, Inc. | System for treatment of acne skin condition using a narrow band light source |
US7354432B2 (en) * | 2003-01-17 | 2008-04-08 | Mcw Research Foundation, Inc. | Red to near-infrared photobiomodulation treatment of the visual system in visual system disease or injury |
US7014639B2 (en) | 2003-02-25 | 2006-03-21 | Skincare Technology, Inc. | Apparatus for aesthetic skin treatments |
KR100495815B1 (en) | 2003-02-26 | 2005-06-16 | 황하욱 | Hair generator |
US20070038269A1 (en) | 2003-02-26 | 2007-02-15 | Photo Therapeutics Ltd. | Therapeutic method and apparatus |
US7354433B2 (en) | 2003-02-28 | 2008-04-08 | Advanced Light Technologies, Llc | Disinfection, destruction of neoplastic growth, and sterilization by differential absorption of electromagnetic energy |
EP2277470B1 (en) | 2003-03-27 | 2013-10-09 | The General Hospital Corporation | Apparatus for dermatological treatment and fractional skin resurfacing |
KR20060041161A (en) | 2003-04-10 | 2006-05-11 | 라이트 바이오사이언스, 엘엘씨 | Photomodulation methods and devices for regulating cell proliferation and gene expression |
US7220778B2 (en) | 2003-04-15 | 2007-05-22 | The General Hospital Corporation | Methods and devices for epithelial protection during photodynamic therapy |
US6861658B2 (en) | 2003-05-24 | 2005-03-01 | Peter D. Fiset | Skin tanning and light therapy incorporating light emitting diodes |
DE10349710A1 (en) | 2003-05-28 | 2004-12-16 | HELBO Medizintechnik GmbH | Arrangement for the reduction of microorganisms |
US20050149150A1 (en) | 2003-07-31 | 2005-07-07 | Light Bioscience L.L.C. | System and method for the photodynamic treatment of burns, wounds, and related skin disorders |
CN1893903B (en) | 2003-09-12 | 2011-03-30 | 雅芒股份有限公司 | Treatment apparatus |
GB2408209A (en) | 2003-11-18 | 2005-05-25 | Qinetiq Ltd | Flexible medical light source |
US7326199B2 (en) | 2003-12-22 | 2008-02-05 | Cutera, Inc. | System and method for flexible architecture for dermatologic treatments utilizing multiple light sources |
US7309335B2 (en) | 2003-12-31 | 2007-12-18 | Palomar Medical Technologies, Inc. | Dermatological treatment with visualization |
US7914523B2 (en) | 2004-02-06 | 2011-03-29 | Clinique Dr Daniel Barolet Inc. | Method for the treatment of mammalian tissues |
WO2005077452A1 (en) | 2004-02-06 | 2005-08-25 | Scyfix Llc | Treatment of vision disorders using electrical, light, and/or sound energy |
AU2005231470B2 (en) | 2004-04-01 | 2011-10-06 | The General Hospital Corporation | Method and apparatus for dermatological treatment |
WO2005096766A2 (en) | 2004-04-03 | 2005-10-20 | The General Hospital Corporation D/B/A Massachusetts General Hospital | Methods and apparatus for treatment of ocular melanosis |
US20070179482A1 (en) | 2004-05-07 | 2007-08-02 | Anderson Robert S | Apparatuses and methods to treat biological external tissue |
WO2005110272A1 (en) | 2004-05-13 | 2005-11-24 | Waverx, Inc. | Apparatus and method for the treatment of infectious disease in keratinized tissue |
WO2005115263A1 (en) | 2004-05-19 | 2005-12-08 | Ostern Co., Ltd. | Low power laser irradiator for treating alopecia |
GB0414113D0 (en) | 2004-06-24 | 2004-07-28 | Virulite Distrib Ltd | Cosmetic uses of electromagnetic radiation |
EP1781374A1 (en) | 2004-07-16 | 2007-05-09 | Johnson and Johnson Consumer Companies, Inc. | Treatment of skin with light and a benefit agent |
GB2416699B (en) | 2004-08-05 | 2010-04-14 | Photo Therapeutics Ltd | Skin rejuvenation |
US20060030908A1 (en) | 2004-08-09 | 2006-02-09 | Lumiport, Llc | Skin treatment phototherapy device |
US20070231255A1 (en) | 2004-08-13 | 2007-10-04 | Derma Laser Inc | Method for the Treatment of Mammalian Skin Tissues Via Pulse Irradiation in the Presence of a Photoactive Compound |
EP1807155A2 (en) | 2004-09-18 | 2007-07-18 | BioLase Technology, Inc. | Output attachments coded for use with electromagnetic-energy procedural device |
US20060265030A1 (en) | 2004-11-12 | 2006-11-23 | Light Bioscience, Llc | System and method for photodynamic cell therapy |
TWI268787B (en) | 2004-12-30 | 2006-12-21 | Ind Tech Res Inst | Light therapeutic device |
US20060173514A1 (en) | 2005-02-02 | 2006-08-03 | Advanced Photodynamic Technologies, Inc. | Wound treatment device for photodynamic therapy and method of using same |
US7258695B2 (en) | 2005-02-08 | 2007-08-21 | Sonetics International | Hair restoration device and methods of using and manufacturing the same |
EP1693016A1 (en) | 2005-02-16 | 2006-08-23 | Wavelight Laser Technologie AG | Medical and/or cosmetic radiation device |
US20060206171A1 (en) | 2005-03-14 | 2006-09-14 | Michael Gertner | Devices, methods and kits for radiation treatment via a target body surface |
US20080294150A1 (en) | 2005-04-01 | 2008-11-27 | Palomar Medical Technologies, Inc. | Photoselective Islets In Skin And Other Tissues |
US7856985B2 (en) | 2005-04-22 | 2010-12-28 | Cynosure, Inc. | Method of treatment body tissue using a non-uniform laser beam |
CA2613294A1 (en) | 2005-05-17 | 2006-11-23 | Photon Therapy Systems (Proprietary) Limited | A photon therapy device |
CN101227949B (en) | 2005-06-17 | 2011-01-26 | 马尔切洛·里纳尔多·巴尔达基尼 | Apparatus for performing human body therapy through electromagnetic wave |
RU2314844C2 (en) | 2005-07-20 | 2008-01-20 | Общество с ограниченной ответственностью "Дипольные структуры" | Method for stimulating basic biochemical reactions in organism for carrying out treatment and tissue recovery, panel for carrying out treatment and tissue recovery and radiator |
WO2007013110A1 (en) | 2005-07-29 | 2007-02-01 | Technodesign Srl | Lighting system for tubs designed to provide well-being with relaxation techniques |
EP1909902A4 (en) | 2005-08-03 | 2009-04-15 | Nomir Medical Technologies Inc | Near infrared microbial elimination laser systems (nimels) for use with medical devices |
WO2007036002A1 (en) | 2005-09-30 | 2007-04-05 | Jason Van Straalen | Light therapy apparatus |
US20070208395A1 (en) | 2005-10-05 | 2007-09-06 | Leclerc Norbert H | Phototherapy Device and Method of Providing Phototherapy to a Body Surface |
US8690863B2 (en) | 2005-10-10 | 2014-04-08 | Reliant Technologies, Llc | Laser-induced transepidermal elimination of content by fractional photothermolysis |
WO2007047892A1 (en) | 2005-10-20 | 2007-04-26 | Light Sciences Oncology, Inc. | External wearable light therapy treatment systems |
US20070156208A1 (en) | 2005-11-08 | 2007-07-05 | David Havell | Method and Apparatus for Bi-Axial Light Treatment |
JP2007151807A (en) | 2005-12-05 | 2007-06-21 | Univ Meijo | Phototherapy method by semiconductor light-emitting element, and phototherapy system by semiconductor light-emitting element |
US20070149901A1 (en) | 2005-12-08 | 2007-06-28 | Em-Probe, Inc. | Methods and apparatus for pulsed electromagnetic therapy |
CN1788645A (en) | 2005-12-12 | 2006-06-21 | 林哲文 | Light conducting hair comb |
US7559945B2 (en) | 2006-01-13 | 2009-07-14 | Clarimedix Inc. | Multi-spectral photon therapy device and methods of use |
US20070168000A1 (en) | 2006-01-13 | 2007-07-19 | Happawana Gemunu S | Apparatus and method for cooling lasers using insulator fluid |
US20070173912A1 (en) | 2006-01-20 | 2007-07-26 | Somnuk Amornsiripanitch | Phototherapy with specific infrared light for treating skin disorders |
EP1983888B1 (en) | 2006-01-24 | 2014-06-25 | Nomir Medical Technologies, Inc | Optical device for modulation of biochemical processes in adipose tissue |
US20090254154A1 (en) | 2008-03-18 | 2009-10-08 | Luis De Taboada | Method and apparatus for irradiating a surface with pulsed light |
US20070179574A1 (en) | 2006-01-30 | 2007-08-02 | Elliott Donald B | Apparatus for phototherapeutic treatment of skin disorders |
EP1818077A1 (en) | 2006-02-03 | 2007-08-15 | WaveLight AG | Phototherapy device for treating the skin |
WO2007091188A2 (en) | 2006-02-06 | 2007-08-16 | Koninklijke Philips Electronics N.V. | Body cover, glasses and/or at least partial head cover, method for radiating at least part of a human body and use of a body cover |
EP1988968B1 (en) | 2006-02-22 | 2011-09-14 | Spencer Forrest, Inc. | Laser hair and scalp treatment device |
ITFI20060053A1 (en) | 2006-02-27 | 2007-08-28 | Cesare Ragazzi | INSTRUMENT FOR THE TREATMENT OF HEALTH AFFECTIONS |
JP2009533076A (en) | 2006-03-01 | 2009-09-17 | ザ ジェネラル ホスピタル コーポレイション | System and method for providing cell-specific laser therapy of atheroma by targeting light absorbers to macrophages |
US20070208396A1 (en) | 2006-03-03 | 2007-09-06 | Gary Whatcott | Systems and methods for providing a dynamic light pad |
US20080031833A1 (en) | 2006-03-13 | 2008-02-07 | Oblong John E | Combined energy and topical composition application for regulating the condition of mammalian skin |
EP1837050A1 (en) | 2006-03-24 | 2007-09-26 | WaveLight AG | Device for the irradiation of the skin |
EP1839705A1 (en) | 2006-03-27 | 2007-10-03 | Universidad de Alcala | Transcutaneous laser therapy patch |
ITBO20060217A1 (en) | 2006-03-30 | 2007-09-30 | Espansione Marketing S P A | DEVICE FOR THE EXECUTION OF AESTHETIC TREATMENTS. |
DE202006005347U1 (en) | 2006-04-03 | 2007-08-02 | Efbe Elektrogeräte GmbH | Infrared light e.g. red light lamp, for e.g. relieving muscle tension, has housing partially surrounded by casing, where air gap that serves as heat isolator is defined between outer surface of housing and inner surface of casing |
US20070239147A1 (en) | 2006-04-07 | 2007-10-11 | The General Hospital Corporation | Method, system and apparatus for dermatological treatment and fractional skin resurfacing |
US20090247932A1 (en) | 2008-04-01 | 2009-10-01 | Daniel Barolet | Method for the treatment of skin tissues |
US20090112192A1 (en) | 2006-04-18 | 2009-04-30 | Daniel Barolet | Method for the Treatment of Skin Tissues |
GB0608315D0 (en) | 2006-04-27 | 2006-06-07 | Univ St Andrews | Light emitting device for use in therapeutic and/or cosmetic treatment |
WO2007126339A1 (en) | 2006-05-02 | 2007-11-08 | Hudoley, Vladimir Nikolaevich | Physiotherapeutic device for light and colour therapy |
JP2007307224A (en) | 2006-05-19 | 2007-11-29 | Ushio Inc | Light therapy equipment |
US8585707B2 (en) | 2006-06-07 | 2013-11-19 | Gary S. Rogers | Continuous low irradiance photodynamic therapy method |
US8246611B2 (en) | 2006-06-14 | 2012-08-21 | Candela Corporation | Treatment of skin by spatial modulation of thermal heating |
JP5010327B2 (en) | 2006-06-26 | 2012-08-29 | パナソニック株式会社 | Hair growth regulator |
KR20090034925A (en) | 2006-06-27 | 2009-04-08 | 팔로마 메디칼 테크놀로지스, 인코포레이티드 | Handheld photocosmetic device |
KR101318968B1 (en) | 2006-06-28 | 2013-10-17 | 서울반도체 주식회사 | artificial solar system using a light emitting diode |
EP1878466A1 (en) | 2006-07-10 | 2008-01-16 | WinStone Technology Corp. | Beauty treatment machine providing infrared light and vibration |
WO2008008971A1 (en) | 2006-07-13 | 2008-01-17 | Candela Corporation | Compact, handheld device for home-based acne treatment |
GB2443470A (en) | 2006-07-24 | 2008-05-07 | En Ltd | Intense pulsed light device with bulb and cooling circuit in removeable cartridge |
US20080031924A1 (en) | 2006-08-02 | 2008-02-07 | Gilson Darcy J | Therapeutic device for delivering controlled air stream flow and/or photodynamic light therapy |
US20100010593A1 (en) | 2006-08-07 | 2010-01-14 | Koninklijke Philips Electronics N.V. | System of plaster and radiation device |
US20080045933A1 (en) | 2006-08-15 | 2008-02-21 | Paul Perl | Multi-broadband pulse emitter and a method for applying an effective dermal treatment |
US20080058905A1 (en) | 2006-09-01 | 2008-03-06 | Wagner Darrell O | Method and apparatus utilizing light as therapy for fungal infection |
US20080065175A1 (en) | 2006-09-09 | 2008-03-13 | Redmond Russell J | Therapeutic radiation device |
WO2008033353A2 (en) | 2006-09-13 | 2008-03-20 | Bernstein Eric F | Laser treatment of pigmented lesions on the skin |
US20080082148A1 (en) | 2006-09-13 | 2008-04-03 | Bernstein Eric F | Laser treatment for skin tightening |
US7850720B2 (en) | 2006-09-23 | 2010-12-14 | Ron Shefi | Method and apparatus for applying light therapy |
ITBO20060735A1 (en) | 2006-10-24 | 2008-04-25 | Rodolfo Pomar | CAP FOR SKIN AND DERMA TREATMENT. |
US20080103560A1 (en) | 2006-10-26 | 2008-05-01 | Lumiport, Llc | Ultraviolet indicator light therapy device |
US20080106896A1 (en) | 2006-11-03 | 2008-05-08 | Biboting International Co., Ltd. | Illumination device for coupling with cup structure |
EP1920798A1 (en) | 2006-11-08 | 2008-05-14 | Roewer, Norbert, Univ.-Prof. Dr. med. | Infrared irradiation device for irradiating human skin |
EP2106198A1 (en) | 2006-12-08 | 2009-09-30 | Sharp Kabushiki Kaisha | Light source and light irradiating device |
EP1935452A1 (en) | 2006-12-19 | 2008-06-25 | Koninklijke Philips Electronics N.V. | Electrochromic device and photodynamic treatment device comprising such an electrochromic device |
TW200836788A (en) | 2006-12-25 | 2008-09-16 | Matsushita Electric Works Ltd | Light radiation hair growth managent apparatus |
US20100152645A1 (en) | 2007-01-09 | 2010-06-17 | Masahiro Ogasawara | Facial Hair-Growth Device and Facial Hair-Growth System |
US20080172114A1 (en) | 2007-01-17 | 2008-07-17 | Lerner Medical Devices, Inc. | Phototherapy handpiece |
US8206426B2 (en) | 2007-01-17 | 2012-06-26 | Lerner Medical Devices, Inc. | Light source and fiber optic brush for light delivery |
US20080176206A1 (en) | 2007-01-18 | 2008-07-24 | Toshiharu Shinoka | Cardiovascular tissue culture substrate |
US20080177255A1 (en) | 2007-01-22 | 2008-07-24 | R3 Connector Systems | Therapeutic coiffuring instrument |
US7815630B2 (en) | 2007-01-25 | 2010-10-19 | Biolase Technology, Inc. | Target-close electromagnetic energy emitting device |
US20100100159A1 (en) | 2007-01-25 | 2010-04-22 | Chosei Hamada | Hair growth modulation device |
US20080200908A1 (en) | 2007-02-01 | 2008-08-21 | Yacov Domankevitz | Light beam wavelength mixing for treating various dermatologic conditions |
RU2499620C2 (en) | 2007-02-02 | 2013-11-27 | Медтек Лайтинг Корпорэйшн | Portable phototherapeutic apparatus |
WO2008097062A1 (en) | 2007-02-06 | 2008-08-14 | Kim, Tae Gyu | Photochemistry laser diode assembly and photochemistry sheet having the same |
WO2008103922A2 (en) | 2007-02-23 | 2008-08-28 | Reliant Technologies, Inc. | Method and device for tightening tissue using electromagnetic radiation |
US20080208295A1 (en) | 2007-02-28 | 2008-08-28 | Cumbie William E | Phototherapy Treatment and Device to Improve the Appearance of Nails and skin |
US20080234669A1 (en) | 2007-03-19 | 2008-09-25 | Kauvar Arielle N B | Method and device for treating skin by superficial coagulation |
FR2913888B1 (en) | 2007-03-21 | 2010-01-01 | Jean Pierre Breda | METHOD AND DEVICE FOR RADIATION IRRADIATION MODULATED PHOTONIC ENERGY |
JP2008246144A (en) | 2007-03-30 | 2008-10-16 | Matsushita Electric Works Ltd | Method and system for hair growth control |
US8968221B2 (en) | 2007-04-17 | 2015-03-03 | Bwt Property, Inc. | Apparatus and methods for phototherapy |
WO2008131343A1 (en) | 2007-04-19 | 2008-10-30 | Mergenet Medical, Inc. | Temporal control in phototherapy |
US20080262576A1 (en) | 2007-04-20 | 2008-10-23 | Alan Austin Creamer | Method, system, and apparatus for somatic treatment |
US20080269848A1 (en) | 2007-04-24 | 2008-10-30 | Conopco, Inc. D/B/A Unilever | Scalp treatment device |
US20080269844A1 (en) | 2007-04-30 | 2008-10-30 | Logslett Kimberly D | Reflective Crib Liner |
US20080275533A1 (en) | 2007-05-04 | 2008-11-06 | Powell Steven D | Display apparatus for providing information and therapeutic light |
ES2432179T3 (en) | 2007-05-04 | 2013-12-02 | Galderma Research & Development | Use of a derivative of naphthoic acid in combination with red and / or blue light for the treatment of acne vulgaris |
US20080281307A1 (en) | 2007-05-09 | 2008-11-13 | Nadine Donahue | Therapeutic device incorporating light and cold therapy modalities |
US7951138B2 (en) | 2007-05-23 | 2011-05-31 | Reliant Technologies, Llc | Pivoting roller tip for dermatological treatment apparatus |
JP2010527680A (en) | 2007-05-25 | 2010-08-19 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | Lighting system |
US8506612B2 (en) | 2007-05-31 | 2013-08-13 | Koninklijke Philips N.V. | Method and system for providing illumination and physiological stimuli |
WO2008146255A2 (en) | 2007-06-01 | 2008-12-04 | Gabriele Giulini | Portable device for the emission of blue-coloured light |
US8187256B2 (en) | 2007-06-15 | 2012-05-29 | Alexander J Smits | Tattoo removal and other dermatological treatments using multi-photon processing |
EP2164567B1 (en) | 2007-06-29 | 2016-01-06 | Alplight | Portable irradiating arrangement |
US20090012586A1 (en) | 2007-07-05 | 2009-01-08 | Lawrence Eliezer Kepecs | Portable wearable cold laser hair growth stimulator and skin treatment system |
JP2009028267A (en) | 2007-07-26 | 2009-02-12 | Panasonic Electric Works Co Ltd | Light irradiating beauty instrument |
ES2357041T3 (en) | 2007-07-31 | 2011-04-15 | Wella Aktiengesellschaft | INFRARED RADIATION DEVICE. |
JP2009034239A (en) | 2007-07-31 | 2009-02-19 | Panasonic Electric Works Co Ltd | Hair-growth adjusting light emitting device |
US20090043293A1 (en) | 2007-08-10 | 2009-02-12 | Eleme Medical Inc. | Multi-module skin or body treatment device and the method of using |
US20100217358A1 (en) | 2007-08-20 | 2010-08-26 | Universite Laval | Artificial light apparatus and its use for influencing a condition in a subject |
US20090082836A1 (en) | 2007-09-20 | 2009-03-26 | Daniel Schell | Methods of applying phototherapy |
US9079022B2 (en) | 2007-09-27 | 2015-07-14 | Led Intellectual Properties, Llc | LED based phototherapy device for photo-rejuvenation of cells |
EP2044974A1 (en) | 2007-10-03 | 2009-04-08 | Aracaria B.V. | Light-emitting diode (LED) light therapy device |
EP2044973A1 (en) | 2007-10-03 | 2009-04-08 | Aracaria B.V. | Light-emitting diode (LED) light therapy device |
US20090105791A1 (en) | 2007-10-23 | 2009-04-23 | Mcginnis William J | Light emitting medical garment device, kit and method of using |
US7955366B2 (en) | 2007-10-26 | 2011-06-07 | Kai-Shu Sung | Biostimulative illumination apparatus |
GB0721374D0 (en) | 2007-10-31 | 2007-12-12 | Univ Strathclyde | Optical device for the environmental control of pathogenic bacteria |
DE102007052108A1 (en) | 2007-10-31 | 2009-05-14 | Jk-Holding Gmbh | Irradiation device with devices to prevent harmful radiation |
US20090143842A1 (en) | 2007-11-02 | 2009-06-04 | Cumbie William E | Phototherapy Treatment and Device for Infections, Diseases, and Disorders |
US20090177190A1 (en) | 2007-11-16 | 2009-07-09 | Seung Yoon Lee | Lowering skin melanin appearance with red light radiation and red light radiation kit therefor |
WO2009064034A1 (en) | 2007-11-16 | 2009-05-22 | Seung Yoon Lee | Lowering skin melanin appearance with red light radiation and red light radiation kit therefor |
US7896908B2 (en) | 2008-01-08 | 2011-03-01 | Oregon Aesthetic Technologies | Skin therapy system |
CN101965534A (en) | 2008-02-28 | 2011-02-02 | 皇家飞利浦电子股份有限公司 | Apparatus for spreading light from multiple sources to eliminate visible boundaries therebetween, light therapy devices including such apparatus, and methods |
US20090234338A1 (en) | 2008-03-11 | 2009-09-17 | Shaser, Inc. | Reducing sensations experienced during light-based dermatologic treatment procedures |
US8083696B2 (en) | 2008-03-14 | 2011-12-27 | Headwaters R+D Inc | Light and massage multi-therapy hairbrush |
EP2291224A2 (en) | 2008-03-18 | 2011-03-09 | PhotoThera, Inc. | Method and apparatus for irradiating a surface with continuous-wave or pulsed light |
JP5192873B2 (en) | 2008-03-28 | 2013-05-08 | パナソニック株式会社 | Hair growth control light irradiation device |
JP4743343B2 (en) | 2008-03-31 | 2011-08-10 | パナソニック電工株式会社 | Hair growth equipment |
WO2009121158A2 (en) | 2008-04-01 | 2009-10-08 | Universidade Federal De Minas Gerais - Ufmg | Photobiomodulation apparatus for preventing and treating mammary trauma and non-infectious teat injuries |
EP2106780B1 (en) | 2008-04-03 | 2016-03-09 | Rodolfo Pomar | Method for treating the scalp to slow and prevent hair loss and kit for performing the method |
JP2011516192A (en) | 2008-04-10 | 2011-05-26 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | Body lighting system using blue light |
ITBG20080024A1 (en) | 2008-04-15 | 2009-10-16 | Dermotricos Srl | DEVICE FOR THE HAIRLIGHTING OF THE SCALP LEATHER WITH LIGHT SOURCES. |
US8452402B2 (en) | 2008-04-23 | 2013-05-28 | Medtronic, Inc. | Optical sensing device for use in a medical device |
US20090270946A1 (en) | 2008-04-25 | 2009-10-29 | Paul Spivak | Therapeutic Light System |
WO2009132585A1 (en) | 2008-04-30 | 2009-11-05 | Yolare Dermaceuticals, Llc. | A novel anti-aging skincare cream, the cosmetic device and cream within |
US20090281048A1 (en) | 2008-05-07 | 2009-11-12 | Pitcher Stephen N | Method and System for Inducing Anti-aging in Skin |
-
2004
- 2004-08-02 US US10/903,483 patent/US20050149150A1/en not_active Abandoned
- 2004-08-02 KR KR1020067002207A patent/KR101160343B1/en active IP Right Grant
- 2004-08-02 WO PCT/US2004/024879 patent/WO2005011606A2/en active Application Filing
- 2004-08-02 CA CA002533129A patent/CA2533129A1/en not_active Abandoned
- 2004-08-02 JP JP2006522123A patent/JP4739202B2/en not_active Expired - Lifetime
- 2004-08-02 ES ES04779826.9T patent/ES2572976T3/en not_active Expired - Lifetime
- 2004-08-02 CN CNA2004800215760A patent/CN101247768A/en active Pending
- 2004-08-02 EP EP04779826.9A patent/EP1648385B1/en not_active Expired - Lifetime
-
2006
- 2006-01-12 IL IL173123A patent/IL173123A0/en unknown
-
2009
- 2009-08-31 US US12/550,464 patent/US9144690B2/en active Active
-
2015
- 2015-07-23 US US14/807,653 patent/US20150328479A1/en not_active Abandoned
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5312395A (en) * | 1990-03-14 | 1994-05-17 | Boston University | Method of treating pigmented lesions using pulsed irradiation |
US5586981A (en) * | 1994-08-25 | 1996-12-24 | Xin-Hua Hu | Treatment of cutaneous vascular and pigmented lesions |
US20020045891A1 (en) * | 1996-08-29 | 2002-04-18 | Clement Robert Marc | Wrinkle reduction |
US6235015B1 (en) * | 1997-05-14 | 2001-05-22 | Applied Optronics Corporation | Method and apparatus for selective hair depilation using a scanned beam of light at 600 to 1000 nm |
US6283956B1 (en) * | 1998-11-30 | 2001-09-04 | David H. McDaniels | Reduction, elimination, or stimulation of hair growth |
US6537302B1 (en) * | 1999-01-20 | 2003-03-25 | Biolight Patent Holding Ab | Means for external medical treatment by means of light |
US6881212B1 (en) * | 1999-03-05 | 2005-04-19 | Icn Photonics Limited | Skin wrinkle reduction using pulsed light |
US6162212A (en) * | 1999-04-19 | 2000-12-19 | Esc Medical Systems, Ltd. | Optimal procedure for performing a hair removal |
US6663658B1 (en) * | 1999-04-27 | 2003-12-16 | The General Hospital Corporation | Phototherapy method for treatment of acne |
US20030004499A1 (en) * | 2000-01-13 | 2003-01-02 | Mcdaniel David H. | Method and apparatus for the photomodulation of living cells |
US20020095143A1 (en) * | 2000-12-18 | 2002-07-18 | Key Douglas J. | Method of amplifying a beneficial selective skin response to light energy |
US20040147985A1 (en) * | 2003-01-27 | 2004-07-29 | Altus Medical, Inc. | Dermatological treatment flashlamp device and method |
Also Published As
Publication number | Publication date |
---|---|
EP1648385A4 (en) | 2009-02-04 |
KR101160343B1 (en) | 2012-06-26 |
JP2007518452A (en) | 2007-07-12 |
KR20060060670A (en) | 2006-06-05 |
US20050149150A1 (en) | 2005-07-07 |
US9144690B2 (en) | 2015-09-29 |
WO2005011606A3 (en) | 2006-12-28 |
ES2572976T3 (en) | 2016-06-03 |
CN101247768A (en) | 2008-08-20 |
JP4739202B2 (en) | 2011-08-03 |
IL173123A0 (en) | 2006-06-11 |
EP1648385B1 (en) | 2016-05-04 |
US20100137950A1 (en) | 2010-06-03 |
EP1648385A2 (en) | 2006-04-26 |
CA2533129A1 (en) | 2005-02-10 |
WO2005011606A2 (en) | 2005-02-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20150328479A1 (en) | System and method for the photodynamic treatment of burns, wounds, and related skin disorders | |
US8651111B2 (en) | Photomodulation methods and devices for regulating cell proliferation and gene expression | |
Kuffler | Photobiomodulation in promoting wound healing: a review | |
Weiss et al. | Clinical trial of a novel non‐thermal LED array for reversal of photoaging: Clinical, histologic, and surface profilometric results | |
Avci et al. | Low-level laser (light) therapy (LLLT) in skin: stimulating, healing, restoring | |
US9737728B2 (en) | Method for the treatment of mammalian skin tissues via pulse irradiation in the presence of a photoactive compound | |
Kohl et al. | Aesthetic effects of topical photodynamic therapy | |
Dierickx et al. | Visible light treatment of photoaging | |
US20060265030A1 (en) | System and method for photodynamic cell therapy | |
Jung et al. | Prospective randomized controlled clinical and histopathological study of acne vulgaris treated with dual mode of quasi-long pulse and Q-switched 1064-nm Nd: YAG laser assisted with a topically applied carbon suspension | |
KR20150032994A (en) | The light therapy by skin improvement and hair restore device | |
Tedesco et al. | Low level energy photodynamic therapy for skin processes and regeneration | |
Wanitphakdeedecha et al. | Local and systemic effects of low-level light therapy with light-emitting diodes to improve erythema after fractional ablative skin resurfacing: a controlled study | |
US20060173512A1 (en) | Method for protecting mammalian skin against upcoming photodamage | |
Railan et al. | Laser treatment of acne, psoriasis, leukoderma, and scars | |
DE602004008661T2 (en) | DEVICE FOR ILLUMINATING A ZONE FROM ANIMAL SKIN | |
US20100081185A1 (en) | System and method for photodynamic cell therapy | |
Edge et al. | Biophotonic Therapy Induced Photobiomodulation | |
Seok et al. | Low-level laser therapy in immune-mediated skin disease: a narrative review | |
Mezzana | “Multi Light and Drugs”: a new technique to treat face photoaging: Comparative study with photorejuvenation | |
US20220168552A1 (en) | Straberi EpiStamp Device | |
Shurrab et al. | Low‐level laser therapy for skin rejuvenation: A safe and effective solution baked by data and visual evidence | |
Sawhney et al. | Low-Level Laser (Light) Therapy for Cosmetics and Dermatology | |
Menezes et al. | Photobiomodulation Using Amber Led and Infrared Laser to Controlling the Pigmentation and Flaccidity from Skin | |
Calderhead | 27 Skin Aging Clock and Its Resetting by Light-Emitting Diode Low-Level Light Therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: ADVISORY ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |